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PREFACE 
I started doing research when I was eleven years old. It was the summer of 1989, one year 
earlier; the Iraqi army had carried out a campaign against the Kurdish population. The army 
destroyed thousands of villages and cities and 182 000 civilian Kurds were sent to the 
concentration camps. My parents, long time activists for the Kurdish cause, together with my 
elder siblings started a survey to collect information on the range of the damages of the 
1988’s genocide campaign. I remember very well sitting with the questionnaires on numbers 
of households per village, or whether the villages had a school or a mosque. Those who 
answered were either refugees who had survived the genocide campaign or members of the 
resistance force, the Peshmerga. Tired faces who with lots of sorrow answered questions 
about their home villages that did not exist anymore.  
A few years later, with the escalating war, I too, had to flee. I ended up in Sweden, which 
became my second homeland where I studied medicine. When the opportunity to be a part of 
this wonderful project on malaria in Zanzibar occurred, it felt just as the right thing to do. 
Malaria is a face of injustice, a terrible disease that hits those who have no means, a threat 
that can be prevented if we did really wanted to.  
The survey I participated in 1989 did not stop the genocide. Our loved ones, friends and 
relatives who were sent to the concentration camps never came back.  But the reports based 
on our survey were used by many human right activists in their efforts to make the genocide 
against the Kurds internationally recognized and hopefully it will help preventing further 
atrocities against people elsewhere. In the same way, I hope that knowledge I have acquired 
while doing work, will make a small contribution to the on-going global efforts to reduce 
malaria burden. After all, this is the reason why we should do research.  
 
 
  
ABSTRACT 
Following the increase of the international funding for implementation of the combined 
malaria control strategies in the past decade, a significant reduction of malaria attributed 
morbidity and mortality has been achieved. Yet, malaria is still a severe threat to global 
health. In 2013, more than 200 million malaria cases causing the death of over 600 000 
people were reported. 
Zanzibar was among the first to implement artemisinin-based combination therapy (ACT) for 
malaria treatment, strengthened vector control measures including long lasting insecticide 
treated nets (LLINs) and indoor residual spraying (IRS) as well as rapid diagnostic test 
(RDT) for malaria diagnosis at peripheral health care facilities.  
We assessed the effectiveness of malaria control tools and interventions for achieving malaria 
elimination in Zanzibar by studying the temporal trends of different malariometric indices in 
two districts of Zanzibar (Micheweni and North A) with a population of approximately 
100,000 people each, between 1999 and 2013. Moreover, we conducted a health facility 
based study in the same districts for evaluation of RDT for malaria diagnosis including its 
performance within the integrated management of childhood illness (IMCI) algorithm as well 
as its field applicability as a source of parasite DNA for DNA extraction for molecular 
surveillance. 
The interventions, with high sustained community uptake, were associated with major decline 
in malaria transmission most pronounced from 2004 to 2007, after which there appears to be 
a steady state. The cross-sectional survey in 2013 revealed a 97.0% reduction of Plasmodium 
falciparum prevalence when compared to 2003. Health facility data showed 96.0 % reduction 
of parasitologically confirmed malaria infections. All cause mortality among children under 
five decreased by 70%. Moreover, the general perception of reduced malaria burden by the 
caretakers was not associated with reduced adherence to the vector control measures. 
RDT sensitivity against PCR and blood smear microscopy was relatively low (76.5% and 
78.6%, respectively). Adherence to the RDT results was excellent (99.9%) and RDT 
performed well in the IMCI algorithm with equally high adherence among children under 
five as compared with other age groups. Further, RDT showed to be a good and reliable 
source of parasite DNA, useful for malaria case detection, molecular surveillance and RDT 
quality control. 
During the conduct of the studies in this thesis, malaria elimination was not achieved in 
Zanzibar. However, following implementation of effective and sustainable tools 
and interventions with high coverage and uptake, Zanzibar has reached a state of malaria pre-
elimination. Additional tools and interventions are necessary for further reduction of malaria 
transmission towards malaria elimination. 
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1 BACKGROUND 
1.1.1 General introduction to malaria 
Malaria is one of the oldest described diseases. The first written evidence of malaria is found 
in the Chinese medical classic Nei Chin (the Canon of Medicine) from 2,700 BC (1). 
The malaria parasite is believed to have had the largest selective impact in recent history of 
the human genome. Many diseases associated with erythrocyte defects such as sickle-cell 
anaemia, thalassemia and glucose-6-phosphatase deficiency have been driven by the 
evolutionary power of malaria (2).  
Due to its complicated life cycle and the its ability to be transmitted by a vector with high 
surviving skills, human beings still have not been able to defeat this disease that has killed 
famos men and women, emperors and warriors, writers and artists and most significantly 
millions of ordinary people around the world.  
During last few years and following the increased funding for malaria control efforts, 
significant reduction of the global malaria burden has been achieved. Since year 2000, 
malaria prevalence and malaria attributed mortality has been reduced by nearly 50%. Reports 
from several countries in Africa have shown a significant decline of malaria incidence 
following deployment of the new global strategy (3-13).  Yet, in 2013, an estimated number 
of 200 (124-283) million malaria cases were reported causing the death of 600 000 to one and 
half million people. The majority (90%) of all malaria deaths occurred in Africa, mostly 
among children under five who accounted for ca. 80% of all malaria attributed deaths (14-
15).  
Malaria is generally seen as “a disease of the poor” (16). The close association between 
malaria and poverty can be easily illustrated by a look at the global maps of poverty and 
malaria distributions. Unsurprisingly these two are to a large degree consistent with each 
other.  People living in poverty spend less on malaria preventive measures such as bed-nets 
and afford less to visit health facilities for their malaria management and hence are at a higher 
risk for malaria transmission than less poor people. Importantly not only poverty can lead to 
an increased burden of malaria but malaria too, can cause poverty and deteriorate it. A lower 
malaria burden leads to positive economical development and can reduce poverty. As malaria 
affects some of the poorest people in the world, reducing malaria burden means a break in the 
cycle of poverty (16-19). 
1.1.2 History 
Malaria (from the Italian mal'aria, "bad air") received its widely accepted name by Romans 
who associated marshes around city of Rome with fever. Being good constructors, the 
Romans conducted a drainage program of the swamps around Rome as the first antimalarial 
intervention. However, malaria and its symptoms and causes have been described much 
earlier. Chinese, Indian, Mesopotamian and Ancient Greeks have all contributed to further 
understanding of malaria. Hippocrates described and classified malaria symptoms and the 
Sanskrit script by Sushruta suggested that malaria is caused by mosquito biting (20). 
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Important milestones in history of malaria were made in the late 19th century when Alphonse 
Laveran, a French army surgeon stationed in Algeria described the malaria parasite in human 
blood in 1880. Another army surgeon, British Ronald Ross discovered oocytes in the wall of 
the stomach of the Anopheles mosquito in India in 1897 and the following year, he described 
the complete life cycle of bird malaria in naturally infected sparrows in Kolkata, India. The 
same year Italian Giovanni Grassi and his colleagues described the cycle of human malaria 
parasites in Anopheles mosquitoes and showed that the sexual phase of Plasmodium takes 
place only in the Anopheles mosquito (21).  
1.2 THE MALARIA PARASITE 
The organism causing malaria is a unicellular parasite, a protozoon of Plasmodium genus. 
There are five species of Plasmodium that can infect human beings: P. falciparum, P. vivax, 
P. ovale, P. malariae and P. knowlesi 
1.2.1 P. falciparum 
P. falciparum is the dominant plasmodium species in malaria endemic areas of Africa. It is 
also found in other tropical and subtropical regions outside Africa. P. falciparum is regarded 
as the most severe plasmodium causing the highest rate of malaria morbidity as well as over 
90% of all malaria mortality (22). This thesis is mainly focusing on P. falciparum as it is the 
dominant malaria species in Zanzibar. 
1.2.2 P. vivax  
P. vivax is the most geographically spread species of five human malaria species. It is the 
dominant plasmodium species in The Americas, Southeast Asia, Middle East and the Pacific 
region (23). P. vivax needs Duffy blood group antigen on the surface of the red blood cells 
(RBC) to invade the cell. The common prevalence of Duffy negative blood group among the 
African population is believed to be the natural selection for rare prevalence of this 
Plasmodium species in major parts of Sub-Saharan Africa especially in West Africa (236). P. 
vivax has the ability to be metabolically inactive and transform into a so-called hypnozoite 
form and relapse several months after its entry into human blood.  
1.2.3 P. ovale and P. malaria  
These two species are less common compared to the previous presented species. P. ovale is 
mostly found in Africa (West Africa) and the Pacific region (24) P. ovale is able to develop 
into hypnozoite and relapse months and even years after the initial infection. 
P. malariae’s distribution is similar to P. ovale but it can also be found in most other malaria 
endemic areas such as in Zanzibar.  
1.2.4 P. knowlesi  
This is the least common species of malaria mostly found in certain regions of South-East 
Asia. P. knowlesi is naturally hosted by macaques monkeys. Zoonotic transmission was until 
recently limited but today P. knowlesi is the main cause of malaria in Malaysia especially on 
the island of Borneo (25) Up to now, there is no evidence of development human-to-human 
transmission of P. knowlesi (26). 
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1.3 MALARIA VECTOR 
The only mosquito genus able to transmit human malaria infection is Anopheles that contains 
more than 400 species of which 70 are malaria vectors (237). The life cycle of Anopheles is 
divided into four stages: eggs which are laid on the surface of water and hatch after ca. 48 
hours into larvae which develops later into pupae and finally to adult mosquitoes. The total 
life span is up to four weeks and the first three stages are dependent on temperature (27).  
There are several different Anopheles species in various geographical settings with different 
capacities of malaria transmission. Anopheles mosquito can be found worldwide except in 
Antarctica and the Pacific islands east of the Vanuatu (the Buxton line) (28). Historically, 
malaria has been a global disease. Even in northern Europe, malaria transmission was 
relatively common until the first decades of the 20th century. In Sweden, malaria was 
eliminated first in 1930s (74). However, the most suitable temperature for parasite 
development inside Anopheles is between 25°-30° C and it normally ceases when the 
temperature is below 16° C and above 35° C (P. falciparum can not complete its growth 
cycle inside an Anopheles mosquito in temperatures < 20° C). The suitable temperature for 
development of Anopheles larvae is between 20°-30° C and the vector itself cannot survive a 
temperature > 42° C. Hence, malaria transmission mostly occurs in tropical and subtropical 
regions in the world on an altitude below 2000 meter (29, 237).  
The feeding behaviour of the Anopheles mosquito is the crucial factor for its transmission 
capability. Anopheles mosquito usually takes its blood meal between dusk and down. 
However, there is a large variation in feeding behaviour among Anopheles species. There are 
early and late feeders. Some are indoor biters (endophagic) and some are outdoor biters 
(exophagic), some prefer bovine blood meals (zoophilic) and some prefer human blood meals 
(antropophilic). The dominant Anopheles species in Africa is Anopheles Gambiae complex, 
which is strongly antropophilic.  
1.4 THE MALARIA LIFE CYCLE  
Figure 1 illustrates the life cycle of malaria parasite. The complexity of malaria transmission 
is partly due to its complicated life cycle involving three different actors: the parasite 
(Plasmodium), the vector (Anopheles mosquito) and the host (human being).  
The life cycle of the malaria parasite begins when the female infected Anopheles mosquito 
bites the host to take a blood meal. The mosquito injects its saliva containing both 
anticoagulants and the asexual sporozoites into the blood vessel of the host. Via the blood 
stream, the sporozoites reach the liver and enter into the liver cells (hepatocytes) within 30 to 
60 minutes. The rapid asexual replication of the sporozoites occurs inside the hepatocytes, 
turning them into mature liver schizonts containing up to 40 000 mature merozoites. This part 
of malaria infection which takes one to two weeks to be completed is asymptomatic and is 
known as the pre-erythrocytic phase. Both P. vivax and P. ovale can upon the invasion of the 
hepatocytes, enter into a low metabolic phase (hypnozoite) and remain inactive for weeks or 
even months before re-activation (relapse). 
When the schizonts rupture, the merozoites that manage to escape the Kupffer cells 
(Macrophages inside the liver) are released into the blood stream and assisted by merozoite 
surface protein, they attach themselves to the erythrocytes, invade them and start the second 
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phase of malaria infection known as the erythrocytic phase. This is a rapid process and takes 
no longer than a minute. After the entry of the merozoites into the erythrocytes, asexual 
multiplications take place and erythrocytic schizonts consisted of 8-24 merozoites are built. 
Upon maturation, these schizonts rupture and merozoites and toxins made in the process are 
released into the blood stream.  The released merozoites attack new erythrocytes and this 
chain reaction is the origin of the periodic fever attacks and shivering that is seen in some 
malaria patients. A fraction of the merozoites do not develop into erythrocytic schizonts but 
turn into sexual forms called gametocytes. Erythrocytes that contain gametocytes do not 
rupture and when another Anopheles mosquito takes a blood meal from an infected host, the 
gametocytes are transmitted to the vector. The fertilization takes place inside the gut of the 
mosquito. Thereafter, new oocytes containing sporozoites are created. Mature oocytes rupture 
and the sporozoites migrate to salivary glands of the mosquito. The cycles in completed when 
these sporozoites are injected into a human host when the next blood meal is taken (30). 
Figure 1: malaria life cycle. Source: CDC http://www.cdc.gov/dpdx/malaria/ 
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1.5 EPIDEMIOLOGY 
In the mid 19th century, malaria transmission occurred almost worldwide. Today, despite 
progresses made in its control, malaria transmission affects around a hundred countries and 
territories around the world and puts more than three billion people at its risk (15, 31).  
Malaria transmission can occur in any area where Anopheles mosquito can survive and 
multiply and human reservoir of malaria parasites can exist. The transmission can also 
happen without involvement of a vector.  It can occur from a malaria-infected mother to her 
foetus during pregnancy (i.e. vertical transmission) or through blood transfusion.  
1.5.1 Malaria endemicity 
Classification of malaria endemicity i.e. quantifying the presence of malaria or its severity in 
a population or area; was historically done by measurement of splenomegaly (enlargement of 
the spleen) among children aged 2-9 years old in community based surveys. This was later 
revised to classification in relation to parasite rate among the population using blood smear 
(BS) microscopy (238).  
According to this system malaria endemicity is divided into four categories based on 
splenomegaly or parasitaemia. These four categories are: 
a) Holo-endemic (>75%): transmission occurs the whole year 
b) Hyper-endemic (51-75%): periods of no transmission during the dry season 
c) Meso-endemic (11-50%): regular seasonal transmission 
d) Hypo-endemic (≤ 10%): intermittent, irregular malaria transmission 
  
The entomological inoculation rate (EIR) i.e. number of infected Anopheles mosquito bites 
per person per unit of time is another method for classification of high and low malaria 
transmission settings. High malaria transmission is a setting where EIR>10 per year and low 
malaria transmission is a setting where EIR <1 per year (239).   
Malaria transmission can also be classified into stable and unstable malaria. In a stable 
malaria setting, malaria transmission is high with no significant changes over years despite 
seasonal fluctuations. Stable malaria transmission settings can be found in holo- and hyper-
endemic areas in Sub-Saharan Africa where P. falciparum is the dominant parasite species. 
Due to the high exposure to the infection, the population develops a high level of immunity. 
In unstable malaria settings that are mostly found in hypo- and meso-endemic areas, malaria 
transmission changes from year to year. Due to fluctuation of malaria incidence, the level of 
immunity among the population is low. P. vivax is the most common malaria species in 
unstable malaria transmission settings. However outbreaks of P. falciparum can also occur in 
these settings (237, 32). 
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Figure 2: Percentage of people living under 2 US$ per day (1995-2013) 
Source: World malaria report, 2014 (15) 
 
 
   
Figure 3:Malaria risk areas of the world from mid-19th century to the present.  
Source: WHO, Global action plan for a malaria free world (18) 
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Figure 4: Country malaria classification 
Classification of countries by stage of elimination, as of December 2013 Source: 
http://worldmalariareport.org/ 
 
 
Figure 5: Percentage of Population at risk of malaria. Source: http://worldmalariareport.org/ 
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1.6 CLINICAL FEATURES OF MALARIA  
The cardinal symptom of malaria is fever. Hence, a patient living or coming from a malaria 
endemic area with a fever or a history of fever in the past 24-48 hours must always be 
investigated for malaria. Clinical manifestation of malaria is divided into complicated 
(severe) and uncomplicated malaria. All malaria species cause uncomplicated malaria but 
severe malaria is mainly due to P. falciparum infection. The uncomplicated malaria can 
develop into severe malaria.  
The first clinical manifestation of malaria (P. falciparum) occurs earliest seven days after the 
initial infection. Malaria is a febrile disease with several unspecific symptoms such as 
headache, abdominal, chest, joint and muscle pain, nauseas and vomiting as well as general 
malaise. In some patients, the so called malarial paroxysm (quick attack or intensification of a 
malaria symptom, including an abrupt temperature elevation accompanied by heavy sweating 
which usually happens in intervals) occurs.   
Uncomplicated malaria is defined as a patient with parasitaemia with one or several of 
following symptoms: 
• Fever or history of fever 
• Headache 
• Cough 
• Diarrhoea 
• Muscle pain 
• Vomiting 
Complicated (Severe) malaria is defined as a patient with parasitaemia with one or several of 
the following symptoms: 
• Impaired consciousness  
• Multiple convulsions: more than two episodes in 24 hours 
• Deep breathing and respiratory distress (acidotic breathing) 
• Acute pulmonary oedema and acute respiratory distress syndrome 
• Circulatory collapse or shock, Hypo-systolia i.e. systolic blood pressure < 80mm Hg 
in adults and < 50mm Hg in children 
• Renal impairment (serum creatinine > 265 µmol/L)  
• Abnormal bleeding 
• Severe normocytic anaemia (Hemoglobin <50 g/L) 
• Hyper-parasitaemia (2.5%- 20%) 
• Hypo-glycaemia (< 2.2mmol/l or < 40mg/dL) 
• Metabolic acidosis (plasma bicarbonate < 15 mmol/L)  
• Hyper-lactataemia (lactate > 5 mmol/L) 
(33, 237)  
Severe malaria is mostly attributed to P. falciparum malaria infection. One reason behind this 
is the capability of the P. falciparum parasite to escape the immune cells by so called 
rosetting and sequestration. During the maturing stages of P. falciparum, cyto-adherent 
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proteins on the surface of the infected RBCs are expressed making them “sticky”. The sticky 
surfaces of infected RBCs bind to uninfected RBCs and form the so-called rosettes (34). The 
cyto-adherent proteins also facilitate the sequestration process in which the infected RBCs 
bind to the endothelium of the deep vessels preventing them from incapacitation by the 
monocytes and macrophages in the spleen (35). Erythrocyte rosetting is crucial for parasite 
sequestration and development of cerebral malaria (36). This condition is characterized by 
rapid progression from headache to convulsions and coma and causes the death of hundreds 
of thousands of children in Africa annually (37).  
The exact pathology of cerebral malaria remains unclear but the widely accepted hypothesis 
for the mechanism of the disease is the series of complicated inflammatory reactions 
including rosetting and sequestration of the infected RBCs resulting in dysfunction of the 
blood brain barrier. The rosettes clog the vessels in the brain and the blood circulation in the 
brain is deteriorated causing cerebral damages.  Further, restriction of the venous blood flow 
caused by the process described above, exacerbates brain oedema resulting in intracranial 
hypertension (37-39). Others explain the pathophysiology of cerebral malaria due to the toxic 
effects of the overproduction of cytokines and other soluble mediators such as tumour 
necrosis factor (TNF-α) and interleukin (IL-1) or nitric oxide (NO) on the central nervous 
system causing coma (40). Cerebral malaria is a potentially fatal condition among both adults 
and children. In addition to cerebral malaria, severe anaemia and hypoglycaemia are also 
associated with malaria attributed mortality in children with severe malaria (240-242).  In 
both adults and children, metabolic acidosis caused by obstruction of blood flow has shown 
to be the best independent predictor of fatal malaria. Metabolic acidosis is in up to 30% 
associated with a deadly outcome (41,42). Neurological sequelae among children who 
survive cerebral malaria are manifested as memory impairment, ataxia, speech disorder and 
blindness (43).  
1.6.1 Malaria and pregnancy 
In high and moderate endemic areas where level of immunity among the population is high, 
the main impact of malaria on the pregnant women is anaemia, which can increase the risk 
for miscarriage, and perinatal death as anaemia caused by malaria infection contributes to 
maternal death as well as low birth weight (LBW=Birth weight <2500 g). LBW is the main 
risk factor for infant mortality. Pregnant women with little or no malaria immunity have a 
three-fold higher risk of developing severe malaria than non-pregnant women in the same 
area. (243). Regardless of the level of immunity, malaria infection increases the risk for both 
maternal and infant mortality. LBW occurs in both high and low endemic areas and among 
pregnant women with both high or low parasite density.  
Malaria in pregnancy is characterized by an accumulation of infected RBCs in the placenta 
which is facilitated by the interaction between infected RBCs and the placental chondroitin 
sulphate A that fills the space between the villi containing the vessels of the mother and 
the embryo. This interaction causes disturbance in the transport of oxygen and nutrition to the 
foetus (44-45). Further, malaria in pregnancy is also associated with increased susceptibility 
to other infections than malaria with negative impact on both mother and the foetus (46). 
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Considering the above, prevention of malaria infection in pregnant women is critical both for 
saving lives of the mother and the child and to prevent the vertical transmission of malaria 
from the mother to the foetus. Use of intermittent preventive treatment in pregnancy (IPTp) at 
least twice during the pregnancy has resulted in a declined number of malaria infection cases, 
reduced proportion of low birth weights as well as lower death rates among both women and 
children (47). Today, the World Health Organisation (WHO) recommends treatment with 
IPTp with sulfadoxine-pyrimethamine (SP) at least twice during the pregnancy for all 
pregnant women who live in stable malaria transmission  areas of sub-Saharan Africa (244). 
1.7 MALARIA DIAGNOSIS 
1.7.1 Clinical algorithm for malaria diagnosis 
The initial symptoms of malaria are not specific. In areas where access to laboratory tools or 
skills is limited, symptom overlap between malaria and other febrile diseases, mainly acute 
respiratory infections especially in children, is a challenge for clinicians (48-50).  
A study in Malawi showed that 95% of the children with the the clinical criteria for 
pneumonia also met the clinical criteria for malaria (51). Presumptive malarial treatment for 
all febrile patients in high malaria endemic regions has been practiced for a long time and 
conditioning antimalarial treatment only upon confirmation of malaria diagnosis has been and 
is a subject of debate (52-55). 
As accurate laboratory methods for diagnosing the aetiology of febrile diseases are not 
available, overuse of both antimalarial and antibacterial drugs are common. Studies have 
shown that a decline of malaria transmission is followed by an increase of treatment with 
antibiotics (56-57).  Improvement of malaria diagnosis becomes even more important when 
some recent studies on fever aetiology among febrile children suggest viruses and not 
bacteria being the main cause of fever among these patients  (58, Elfving et al, submitted). 
1.7.1.1 Integrated Management of Childhood illness 
Integrated Management of Childhood illness (IMCI) is an algorithm used for management of 
illness in children aged 2–59 months in low and middle-income countries. IMCI’s focus is 
not disease-specific. It is a guideline for health personnel at the first level health care facilities 
to classify conditions of an ill child through clinical assessment, classification, treatment, 
advice and follow up. The aim of IMCI is to decrease mortality and morbidity of children by 
improvement of the case management capacity of health system as well as the family and the 
community practices (59). 
IMCI guides the health workers to assess the sick child in order to identify the danger sign/s, 
then classify the ill children into three categories: 
• Ill children who must be urgently referred to a second level health care facility  
• Ill children who can be managed by specific medical treatment and advice and 
• Ill children who require only simple advice on home management  
The caretaker receives practical advices regarding treatment. Depending on the child’s 
condition, follow up instructions to the caretaker are provided (60). IMCI guidelines are 
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adapted for different regions and countries in order to cover the most common diseases in the 
specific regions and to be consistent with the national treatment guideline in order to facilitate 
their implementation with regards to the health system and the society in general (61).  
Evaluation studies on IMCI effectiveness suggest that the IMCI guidelines increase quality of 
care, reduce overall costs as compared with vertical child health programs and in some 
setting, reduce childhood mortality (62, 63). Moreover, IMCI guidelines have shown to 
improve the use of antibiotics at the first level health care facilities (64) and the management 
of pneumonia, gastroenteritis, measles and malnutrition. However, when no BS microscopy 
was used for malaria diagnosis, a significant overtreatment with antimalarial medicines was 
observed (65).  
1.7.2 Parasitological confirmed malaria diagnosis 
Rapid diagnosis and treatment of a potential fatal disease as malaria is critical for prevention 
of death and other severe consequences due to the disease. Until recently, parasitological 
confirmation of malaria diagnosis in high endemic areas was not considered as cost effective 
and presumptive treatment of all fever cases was recommended (237). Following a significant 
increase of funds for malaria control during the 2000s and introduction of Rapid diagnostic 
test (RDT) for malaria diagnosis, WHO is now recommending parasitological confirmation 
of malaria diagnosis before treatment with antimalarial drugs (66).   
1.7.2.1 Malaria microscopy 
Light microscopy of stained BS is considered to be the gold standard in malaria diagnosis as 
this method has several advantages: it is relatively cheap, it differentiates between different 
malaria species, it can be used for quantification of parasite densities and it can identify 
different parasite stages (67, 68). 
Parasite quantification is done by counting number of parasites observed in the thick smear 
against a standard number of white blood cells (WBC). In order to determinate the parasite 
density, the following formula is commonly used: 
(Parasites counted/ number of WBC counted) X 8000= Parasites/µl  
An alternative quantification method is, determination of parasite density as a percentage of 
infected RBCs on the thin film (67, 69,70).  
The sensitivity of malaria microscopy under ideal conditions is very high with a detection 
limit down to 5-10 parasite/µl. But it is highly dependent on the microscopist and the quality 
of BS. In real life, at peripheral health care levels in low-income countries, the detection limit 
is about 100 parasite/µL (71). Since malaria microscopy is a time consuming and work 
intensive procedure, it can lead to fatigue and reduced diagnostic accuracy of the 
microscopist (72).   
1.7.2.2 RDT  
In 1990s, RDT was introduced as an alternative method for malaria diagnosis in febrile 
patients in settings where access to malaria microscopy was not optimal. Following this, the 
testing rate increased annually. In 2013, for the first time in Africa, the number of conducted 
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malaria diagnostic tests was higher than the number of prescribed artemisinin-based 
combination therapy (ACT) doses. As the number of malaria diagnosis by BS microscopy 
was not changed, the increased number of tested patients was attributed to use of RDTs for 
malaria diagnosis (15). 
The detection limit of RDTs is almost equal to those of good field microscopy i.e. (~100 
parasites/ µL) (73). However, there is a major variety in the sensitivity of different RDT 
products (245). The recommended level of sensitivity is ≥95% for detection of ≥100 p/µL and 
a minimum 90% for all malaria species compared with BS microscopy (71, 75). Moreover, 
several studies have shown a vast variety in the sensitivity of RDTs in the field have been 
shown in different studies (56, 76-78). 
Basic principal of the malaria RDT is the detection of parasite antigens. Parasite antigens 
detected by RDTs are: Histidine-Rich Protein-2 (HRP-2), Plasmodium Lactate 
Dehydrogenizes (pLDH) and Aldolase-pan malaria antigen. 
HRP-2: HRP-2 is a histidine- and alanine-rich protein localized in the P. falciparum 
cytoplasm as well as in the infected erythrocyte’s membrane and is therefore the target for the 
RDT. It is a water-soluble and heat-stable protein that is synthesized only by P. falciparum 
parasites (258). HRP-2 has a long half-life and can remain detectable several weeks after 
completed malaria treatment (79, 80). 
Plasmodium falciparum histidine reach protein 2 (PfHRP-2) is expressed in gametocytes and 
all blood stages of P. falciparum. As this protein is released when the schizonts rupture, 
HRP-2 based RDTs can detect the sequestrated parasites that may escape the detection by 
microscopy. This can happen during pregnancy when malaria parasite sequester in placental 
tissues and avoid detection by microscopy (81). 
pLDH: LDH is an enzyme and marker of different tissue damages and illnesses. pLDH is 
expressed massively by malaria parasites as it is produced in the glycolytic cycle of the 
asexual stage of all species of plasmodium (82), however pLDH’s isoform can be 
differentiated from human LDH (83) and, pLDH-based RDTs can distinguish between 
falciparum and non-falciparum malaria infections. Moreover, pLDH is cleared from the 
blood stream after completed treatment much earlier than HRP-2 (84). 
Aldolase-pan malaria antigen: Aldolase is “a major enzyme involved in the glycolytic cycle 
of Plasmodium and is released into the blood during infection”(85). Aldolase is a pan-specific 
antigen for Plasmodium detection since a large part of its amino acid sequences is relatively 
preserved in all Plasmodium species (85, 86). As the sensitivity of Aldolase based RDTs has 
shown to be low and dependent on parasite density (81), commercial use of Aldolase-based 
RDTs is not common. 
1.7.2.3 Test principle of RDT 
RDT is an immunochromatic test that detects malaria specific antigens. RDT is conducted by 
application of a few drops of capillary or venous blood on the RDT device. The labelled 
antibodies prepared against malaria antigen target is mixed with the blood. A few drops of 
lysing buffer are added to the sample for antigen release and antibody recognition. The 
testing process relies on the migration of liquid (blood and buffer) across the surface of a 
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nitrocellulose strip in the cassette test device. A capture antibody is bound to the 
nitrocellulose strip. If malaria antigen is present the labelled antibody-antigen complex will 
migrate along the nitrocellulose strip until it reaches the bound capture ab. The capture 
antibody binds to the labelled antibody-antigen complex and produces a visible line. In order 
to control the correct performance of the test i.e. to control the test for migration, another 
antibody capture specific for another epitope of the labelled abs is applied to the 
nitrocellulose strip for formation of the control line (87). RDT is able to detect the malaria 
parasite within 15-30 minutes. 
Recently RDTs with combination of HRP-2 and pLDH enabling detection of both P. 
falciparum and other malaria species (P. vivax, P. ovale and P. malariae) has become 
available in some regions. However, these RDTs still cannot determine the exact species of 
non-falciparum malaria parasites.  
RDTs are simple and user friendly and the device is tolerant for major different climatic 
conditions. An RDT device weighs only a few grams making it easy to transport and suitable 
for use in the field in different settings. RDTs are more expensive (per test) than microscopy. 
Yet, whilst microscopy requires good microscopes and qualified microscopists, blood 
staining facilities and electricity, the use of RDT requires none of these. Furthermore, RDTs 
have shown to be cost-effective since they improve management and health outcomes for 
non-malarial febrile patients as well as reduce the costs associated with prescription of 
expensive ACTs to RDT negative patients (56, 88, 89).   
The significance of the RDTs in malaria surveillance has grown recently as the DNA from 
malaria parasites can be reliably extracted (See below). This can be used for molecular 
analysis such as detection of low level of parasitaemia below the detection limits of RDT and 
BS microscopy as well as drug resistance monitoring directly from RDTs stored during 
several months in tropical climate (90).   
RDT has some disadvantages: it cannot determine parasite densities. Further, the HRP-2 
based test remains positive several days, or even weeks after completed antimalarial 
treatment that prevents assessment of the clinical outcome of the treatment (91). Other issues 
such as RDT performance in the field situation as well as health workers’ adherence to the 
test result have been studied and debated for a while. There are concerns regarding the safety 
of withholding antimalarial medicines to patients with negative RDT result. Depending on 
different epidemiological settings and health systems, the findings and conclusions are 
different and sometimes contradictory to each other (54-56, 76, 92-94). Nevertheless, ACTs 
are expensive and as mentioned earlier in settings with no access to microscopy facilities, 
presumptive treatment with ACT may prevent correct diagnosis for other and potentially 
deadly diseases. RDTs improve targeting of antimalarial treatment to malaria patients and 
may facilitate a more accurate case management of other febrile diseases (95). There is also 
the risk inducing the development of anti-malarial drug resistance with devastating effect on 
global malaria control efforts through overuse of the ACTs (96-98). After initial 
recommendation of use of RDTs for malaria diagnosis in settings where BS microscopy is 
not available (66) WHO started its new initiative called T3: Test. Treat. Track, in 2012 
calling on the global malaria community to scale up diagnostic testing, treatment and 
surveillance for malaria in which RDT would play a significant role (99). 
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1.7.3 Molecular based diagnostic methods 
As described earlier, the detection limits of both BS microscopy and RDTs do not allow 
detection of low parasitaemia carried by asymptomatic individuals in malaria endemic areas 
but these persons are still a potential reservoir for malaria transmission (100). Different 
molecular based diagnostic methods with high sensitivity for detection of very low 
parasitaemias are described below 
1.7.3.1 DNA extraction 
In order to detect malaria parasites with molecular methods, DNA is extracted from either 
fresh blood or blood dried on RDT (during the testing) or filter paper (FP).  There are several 
methods for DNA extraction. The most common method when using small quantities of 
blood is Chelex-100, a cheap method which stability for further analyses decreases the longer 
storage time is (101). Simple elusion method is similar to Chelex-100. This is a more rapid 
method but is in comparison to Chelex-100 less stable (102). Column based methods (e.g. 
Qiagen or ABI) are used for larger volumes of DNA and for long DNA fragments. This 
method provides a better and more stable DNA quality but is more expensive and more 
laborious than the other two methods (246).  
1.7.3.2 Polymerase Chain reaction (PCR) 
The principle of the PCR technique is amplification i.e. converting very low quantities of 
DNA into very high quantities. The first report about the original method was published in 
1985 (103). PCR technique relies on so-called thermal cycling i.e. heating and cooling. Each 
PCR cycle consists of three main steps and takes few minutes to complete.  These steps are:  
Denaturation: The biological material containing the original DNA sequence to be 
replicated is heated rapidly to 94°-96° C in order to melt the DNA sequence and separate the 
double stranded DNA into single-stranded DNA.  
Annealing: The temperature is suddenly cooled down to ca. 68° C which enables the specific 
primer (a short DNA fragment complementary to the target DNA) to bind to the 
complementary DNA sequence of the single-stranded DNA template. Taq-polymerase (an 
enzyme responsible for building the DNA molecule by joining the nucleotides together 
creating a mirror image of the template) is attached to the double stranded DNA that is a 
formation of the primer and its complementary DNA sequence. 
Elongation: The temperature is raised again to ca. 72° C and DNA polymerase synthesizes a 
new DNA strand complementary to the DNA template strand by adding deoxynucleotide 
triphosphates (dNTP).  At the end of the cycle the temperature will rise again to 94°-96° C 
again for denaturation of the newly formed double stranded DNA and a new cycle will start 
(104, 247).  
Real-time PCR or Quantitative PCR (qPCR) is a type of PCR-method enabling quantification 
of the desired product at any point in the amplification process by measuring the emitted 
fluorescence. Fluorescence is “the emission of light by a substance that has absorbed light or 
other electromagnetic radiation” (Wikipedia). The increase of the emitted fluorescence  
during each PCR cycle is proportional to the amount of PCR product. The levels of 
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fluorescence are measured at each PCR cycle by a detector. This method is called “real time 
PCR” since it measures the amplification as it occurs. This is assessed after every PCR cycle 
by measuring the quantity of fluorescence emitted while each double stranded DNA is 
produced. When the fluorescence is plotted against the number of cycles on a logarithmic 
scale, a threshold for detection of DNA-based fluorescence is set just above the background. 
The number of cycles at which the fluorescence exceeds the threshold is called the cycle 
threshold (Ct) (104, 105) 
One of the earliest methods of nested PCR for parasite detection was designing 
primers targeting the small subunit ribosomal RNA (18S(r) RNA) genes of the four major 
human Plasmodia species i.e. P. falcipaurm, P. ovale, P. malariae and P. vivax (106). Later, 
the more sensitive method of targeting Cytochome b (Cyt b) gene in the mitochondrial DNA 
of all human Plasmodium species was introduced (107). 
The detection limit of the PCR is between 0.05-10 parasite/µl, making it the most sensitive 
method for malaria parasite detection (108, 109). Moreover, PCR can identify all different 
types of human plasmodium species and mixed infections as well as quantify parasite rate. It 
can be used for screening of the entire population of large communities since DNA extraction 
can be done from blood stored on FP and RDTs (90, 110). However, PCR is expensive, 
requires advanced laboratory equipment, electricity and skilled personnel and therefore not 
possible to be used for routine malaria case management.  PCR is mostly used for quality 
control of BS and RDT, monitoring of the malaria control programs as well as in research on 
the development of anti-drug resistance in parasites and drug efficacy trials (111).  
1.7.3.3 Loop mediated isothermal amplification  
More cost-effective molecular methods with lower demand on technical skills and advanced 
laboratory techniques are sought and research is on going. One method is the use of Loop 
Mediated Isothermal Amplification (LAMP), which can mass-amplify a few copies of DNA 
in a relative short time and under isothermal condition (248) It has shown promising results 
for the possibility of deployment of molecular techniques that can improve the diagnosis as 
well as surveillance of low-density parasitaemia in malaria elimination settings (112,113).  
However, parasite quantification cannot be done by LAMP. 
1.7.4 Serology 
This is another method of malaria diagnosis based on detection of antibodies against 
erythrocytic stages of malaria parasites. Serological markers can be used for evaluation of 
malaria transmission intensity and assessment of annual burden of malaria transmission as 
well as analysis of long-term trends in malaria transmission within and between communities 
in the same area (114).  
Serology detects malaria parasite antibodies that are produced within two weeks after the 
initial infection and cannot differentiate between current or cured malaria infections. Thus, 
this method is not useful for clinical malaria diagnosis but is used for epidemiological studies 
as well as screening of asymptomatic infections among blood donors. 
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1.8 ANTIMALARIAL DRUGS  
Things have definitely changed in malaria treatment since the time of the Romans when 
Sammonicus, who was the personal physician of the Roman emperor Caracalla, instructed his 
patients who had malaria to wear an amulet with the inscription “Abracadabra” meaning it 
came to pass as it was spoken (115)! But the path has been too long and the search for the 
perfect drug is still not completed. 
Throughout history, there have been numerous traditional medicines for malaria treatment. 
Two important medicines used today (quinine and artemisinin) have both originated from 
traditional herbal medicine. As malaria has been a much more serious threat to poor countries 
in the tropical and subtropical climate zones, the development of the antimalarial drugs has 
not been in relation to malaria’s impact on human life. The industry, drug companies and 
researchers’ efforts to develop effective antimalarial drugs have been mostly formed by the 
need of soldiers involved in wars fought in malaria endemic regions and not patients living in 
those countries. 
Jesuit missionaries in South America learned the use of Cinchona bark for malaria treatment 
from Native Incan herbalists. This was later named as Peruvian bark or Jesuit powder. The 
name Quinine originated from Incan word Quina-quina that means ”holy bark”. In 1820 the 
active alkaloids from the bark was isolated and named by French scientists Pelletier and 
Caventou. Quinine was used for malaria prophylaxis from mid 19th century. In order to meet 
the demands for quinine, large areas in Southeast Asia, particularly in Indonesia were made 
available for cultivation of Cinchona tree.  Access to quinine contributed to the colonization 
of Sub-Saharan Africa, where malaria was a natural barrier for European colonizer to enter.  
When Japanese troops controlled large territories in Southeast Asia during World War II, the 
allies’ access to quinine reduced significantly. With limited access to quinine, thousands of 
soldiers stationed in Africa and the Pacific died from malaria.   
In 1934, a new synthetic antimalarial drug named chloroquine was developed in Germany. 
Initially, it was ignored for a long time as it was considered to be toxic to human beings. 
After World War II, chloroquine was approved in the USA and used as antimalarial drug for 
decades to come (116). Despite the observation of the first signs of resistance against 
Chloroquin in late 1950s in some areas in Thailand and some remote areas in Venezuela and 
Colombia (117) and later development of widespread resistance against the drug globally, it 
remained as the drug of choice in large parts of Africa since alternative medicines were not 
available. Today, the use of chloroquine for uncomplicated P. falciparum treatment is not 
recommended unless in areas where resistance has not developed yet as well as for treatment 
of P. vivax (in combination with primaquine), P. ovale and P. malariae.  For treatment of 
chloroquine-resistant P. vivax, ACTs combined with primaquine is recommended (66).  
The first document on the use of Artemisia annua for malaria treatment is from the mid 4th 
century (118) but it was during the Vietnam War and by order of Chairman Mao, that a group 
of Chinese researchers started the project 523 to find a sufficient treatment for malaria in 
1967. The meeting to discuss short and long term goals for development of antimalarial drugs 
was held on May 23rd and thus the name “project 523”. Extracted artemisinin from the 
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Artemisia annua showed to be a useful antimalarial drug. Combination therapy with other 
substances that together with artemisinin could enhance the antimalarial effect of the drug 
was suggested in early 1980s.  The so called open door policy initiated by chair man Deng 
Xiaoping in the late 1970s (249), facilitated collaboration between China and commercial 
drug companies and resulted in manufacturing of ACTs in late 1990s (119, 120). In 2001 
ACTs were presented in WHO’s list of essential drugs (259). Since 2006 ACTs are 
recommended as the drug of choice for first line treatment of uncomplicated malaria by 
WHO (66). 
1.8.1 Rational behind combination therapy 
Similar to some other diseases such as Tuberculosis or AIDS, mono-therapy for malaria can 
end up in development of drug resistance. Using the active metabolite of artemisinin 
compounds i.e. (artesunate, artemether, dihydroartesunate) with a partner drug showed to be 
effective for malaria treatment especially after development of global resistance against 
chloroquine (23,121).  
Artemisinin and its derivatives such as artesunate or artemether are the most robust and rapid 
acting of all antimalarial drugs. Their capacity to reduce the infecting malaria parasite 
biomass is 10-100 times higher than other antimalarial drugs (122,123). Combination of 
artemisinin and its derivatives with a partner drug such as Lumefantrine or Mefloquine 
enables the rapid-acting artesunate or artemether to reduce parasite biomass quickly, whilst 
the slow-acting residual partner drug kills the remaining parasites that escaped from 
artemesinin. Moreover, the combination therapy may delay the development of drug 
resistance (124-126).  
The main five common combination therapies recommended by WHO for treatment of 
uncomplicated P. falciparum malaria are: (artemether plus lumefantrine, artesunate plus 
amodiaquine, artesunate plus mefloquine, artesunate plus sulfadoxine-pyrimethamine and 
dihydroartemisinin plus piperaquine) (66) 
1.8.2 The development of antimalarial drug resistance in P. falciparum 
Genetic alterations expressed as single nucleotide polymorphisms (SNPs) associated with 
development of drug resistance in a parasite population are used for molecular surveillance 
and assessment of malaria drug resistance (127, 128). Some of the genes found to be involved 
in drug resistance include:  
P. falciparum Chloroquine resistance transporter gene (pfcrt), P. falciparum multidrug 
resistance 1 gene (pfmdr1) and P. falciparum multidrug resistance protein 1 (pfmrp1) (129). 
P. falciparum Chloroquine resistance transporter gene (pfcrt): SNPs in this gene are showed 
to cause a significant reduction in the accumulation of the chloroquine in the digestive 
vacuole of  the Plasmodium parasite where chloroquine exerts most of its effect (130). 
Additionally, it has been shown that pfcrt may be involved in resistance to other quinolones 
(131). 
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P. falciparum multidrug resistance 1 gene (pfmdr1): SNPs in this gene are associated with 
multidrug resistant phenotypes in Plasmodium parasite with regards to drugs such as 
mefloquine and artesunate (122, 132). 
P. falciparum multidrug resistance protein 1 (pfmrp1): SNPs in this gene have also 
been shown to be associated with response to antimalarial drugs (133). 
As mentioned earlier, about a decade after deployment of chloroquine as the first established 
malaria chemotherapy, signs of resistance were observed in Southeast Asia and later South 
America. When new drugs were introduced later in the 60s and 70s, malaria parasites 
managed to develop resistance against them, too. After initial reports on prolonged parasite-
clearance times from the Thai-Cambodian border (96, 134, 135), P. falciparum resistance 
against artemisinin across mainland Southeast Asia is now reported (135).  
Recently, an increased prevalence of genetic markers associated with artemether-
lumefantrine tolerance or resistance in Africa after deployment of artemether-lumefantrine as 
first-line treatment for uncomplicated malaria was observed (136).  
1.9 VECTOR CONTROL MEASURES 
Although the clear connection between mosquito and malaria transmission was first 
discovered in late 19th century, malaria control has historically been done through 
environmental measures focusing on vector control. The initially successful malaria 
eradication attempt in the mid 50s and 60s, which resulted in malaria elimination in many 
countries around the world, was achieved mainly by vector control (137). 
Current methods used for vector control around the world include chemical methods such as 
residual insecticides and mosquito nets, environmental methods such as drainage and 
biological methods such as use of Larvivorous fish (138,139).  
Chemical methods are the most commonly used methods of malaria control are chemical 
methods such as residual insecticides and mosquito nets.  
1.9.1 Residual insecticide 
The principle of using insecticide residual spraying (IRS) is based on the Anopheles’ feeding 
and resting behaviour. After taking its blood meal, the Anopheles lands on a closest indoor 
surface to rest and digest the blood meal for several hours. If the indoor surface is treated with 
a residual insecticide, the Anopheles will die before it is capable to transmit malaria. The 
most known insecticide, Dichlordiphenyltrichloroethane (DDT) was synthesized in 1870’s 
but its insecticidal effect was first discovered by a Swiss scientist H. Müller in 1939 (140). 
During the WWII, the allies used DDT mostly against Typhus. Later in the 40’s and 50’s it 
was used on a broad scale to fight malaria mosquitoes preliminary in Europe and USA. The 
campaign resulted in great success in Europe and North America but showed to be much less 
successful when used in areas with stable malaria transmission (See below) (141).  
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1.9.2 Mosquito net 
Use of bed-nets for protection against mosquito biting is documented as early as 2700 BC in 
China (1). Insecticide treated nets (ITN) were developed in the1980’s for vector control and 
launched by WHO in late 1990s (142, 143).  
Numerous studies have shown a large protective impact of ITNs and effect on malaria 
transmission. ITNs have shown to reduce malaria morbidity by 25% to 50% and to reduce 
child mortality by 20% (144, 145). It has also been shown that ITNs are providing protection 
to everyone in the community with high ITN coverage as it reduces the number of infected 
mosquitoes in general (146).  
In recent years, the use of Long-lasting insecticidal nets (LLIN) is becoming more common. 
LLINs are pre-treated with insecticide upon the manufacturing and the insecticidal effect lasts 
for 4-5 years, hence no re-treatment is needed (147). 
Significant reduction of malaria burden following intervention with IRS in recent years has 
been reported (13). However combination of both IRS and LLIN has shown to be even more 
effective (148). Moreover, use of different types of insecticides in combined interventions 
may improve management of vector resistance against the insecticides (149).  
1.9.3 Vector development of resistance against insecticides 
The Anopheles mosquito has shown to be able to adapt to different environments. It has been 
effective in developing resistance/tolerance against insecticides and changing its feeding and 
resting behaviour (237, 250). Anopheles resistance against DDT was widespread globally just 
a few years after deployment of DDT for vector control (150).  
In addition to DDT, other more commonly used insecticides for vector control are: active 
component of pyrethrum flowers (pyrethrins) or its synthetic form (pyrethoroids) and 
carbamates as well as organochlorines and organophosphates. The most commonly used 
insecticides for vector control used in LLIN and some IRS are pyrethroids.  
Several recent reports from different parts of Africa have shown changes in the vector 
population towards presence of outdoor-active and early-feeding Anopheles population (i.e. a 
decline of indoor active An. gambiea s.s. and an increase of the outdoor active An. 
arabiences). This highlights the risk of failure of current used vector control interventions 
(mosquito nets that focus on indoor biting mosquitoes)  (151- 155). 
Unfortunately with increasing vector resistance against pyrethroids and other commonly used 
insecticides, the long-term effectiveness of LLIN and IRS is in jeopardy. This highlights the 
urgent need for developing more effective vector control measures (156-158).  
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Figure 6:  John Singer Sargent (1856-1925), Mosquito Nets, 1908, American. Oil on canvas.57.1 × 71.7 cm. 
Courtesy of the Detroit Institute of Arts (http://www.dia.org/), Detroit, Michigan; Founders Society 
Purchase, R. H. Tannahill Foundation fund, 1993.18/The Bridgeman Art Library, New York, New York 
(159).  
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2 MALARIA CONTROL, ELIMINATION AND ERADICATION 
Malaria control is defined as reducing malaria morbidity and mortality to a locally acceptable 
level through use of current available tools for prevent and cure of the disease. Malaria 
elimination refers to “reducing the incidence of locally acquired malaria infection in a 
specific geographic area to zero” while malaria eradication is defined as “reducing the global 
incidence of malaria to zero” (18). After child immunization, malaria control is the most cost-
effective health intervention. The cost for malaria elimination however, is much higher (18, 
160). 
2.1 INITIAL SUCCESS AND FAILURE 
WHO initiated Global Malaria Eradication Program (GMEP) in 1955. The main tools to 
achieve malaria eradication were use of DDT for vector control and chloroquine for malaria 
treatment (141). 
Whilst the main vector in temperate zones with seasonal malaria transmission and cold 
winters are more zoophilic species of Anopheles, the dominant Anopheles species in in Sub-
Saharan Africa are strongly anthrophilic (161). By the end of 19th century and early 20th 
century, malaria had already started to decline in Europe and North America. Improved living 
conditions that reduced the contact between humans and the vector in combination with 
seasonality of malaria transmission as well as improved public health are believed to be the 
main factors behind the spontaneous decline in malaria in these parts of the world. 
Implementation of DDT was a successful contribution that resulted in elimination of malaria 
in almost all Europe and North America in 1950s (162). 
The attempt to eliminate malaria in the rest of the world especially in Africa ended in failure 
mainly due to lack of efficient infrastructure, development of vector resistance to DDT and 
later parasite resistance to chloroquine in combination with dominance of anthrophilic 
Anopheles species and fatal P. falciparum malaria. In 1969, GMEP was eventually 
abandoned (141). 
2.2 NEW GLOBAL STRATEGY AND CHALLENGES A HEAD 
The years of 1970s and 1980s were the dark period in modern history of malaria control. In 
addition to above mentioned factors, economical crisis in the beginning of 70’s, political 
instability, operational difficulties and lack of field-related research were among the factors 
contributing to the deterioration of the situation. In 1998, the Roll Back Malaria (RBM) 
partnership was launched as an effort to provide a coordinated global response to malaria 
transmission (163).  The new strategy of malaria control, which replaced the previous 
eradication strategy, were introduced as: 
• “Control of malaria to reduce the current burden and sustain control as long as 
necessary  
• Eliminate malaria over time country by country and 
• Research on new tools and approaches to support global control and elimination 
efforts” (164).  
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In 2000, the head of African states set out to “halve malaria mortality by 2010” through 
implementation of RBM’s malaria control strategy (165, 142).  Further, fighting malaria was 
made one of the United Nations’ millennium development goals (MDG). However the direct 
and indirect association of malaria with child mortality, maternal health and poverty, makes it 
an equally important element of reaching the other MDGs, too (166). 
In 2005, the global goal was set to “ensure that at least 80% of those at risk of, or suffering 
from, malaria benefit from major preventive and curative interventions by 2010. This would 
reduce the burden of malaria by at least 50% by 2010 and 75% by 2015” (167). 
WHO updated these targets in 2011 to the following:  
• “Reduce global malaria deaths from 2000 levels by 50% in 2010 and to near zero 
preventable deaths in 2015. 
• Reduce global malaria cases by 75% by end 2015 (from 2000 levels). 
• Eliminate malaria in 8-10 countries by 2015 and afterwards in all countries in the pre-
elimination phase today”.  
In a long-term perspective, malaria eradication would be reachable by “reducing the global 
incidence to zero through progressive elimination in countries” (168).  
However, in 2013 less than 50% of the population in sub-Saharan Africa had access to an 
ITN in their household (15). 
2.3 FROM CONTROL TO ELIMINATION 
Malaria elimination requires three fundamental elements: prevention, treatment and 
surveillance (169). Moving from malaria control to elimination goes via pre-elimination. It is 
a transmission state in which the slide (or RDT) positivity rate (SPR) of all febrile patients 
with suspected malaria is <5% or when malaria incidence is <5/ 1000 people at risk in a 
specific region. This requires scale up of malaria control measures as well as general 
enhancement of the health system to reach a sustainable malaria control i.e. maintain and 
gradually improvem the achieved low malaria transmission status (170,165). 
A crucial task in this process is how to avoid malaria resurgence defined as “the reappearance 
of new infection in significant numbers after reduction of malaria transmission by malaria 
control efforts” (171,172). Between 1930-2000 more than 70 resurgence events in 63 
countries were observed of which most of them were associated with weakness of the malaria 
control programs (172).  
The process of moving from malaria control to pre-elimination and later elimination requires 
reorientation of the activities of the national malaria control program. This includes reduction 
of the parasite reservoir through early diagnosis and treatment with effective medicines. 
Further, health information system needs to be strengthened to ensure a sustainable access to 
malaria control measures, entomological monitoring as well as management of the imported 
malaria cases (169, 173). Surveillance, in particular, is considered to be a main component of 
any program aiming to interrupt malaria transmission completely (174) (See figure 7). Who 
gets malaria, where and when the malaria transmission occurs in any specific transmission 
setting are of great importance for a successful approach towards malaria elimination. 
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Coordinating research to obtain knowledge on the on-going changes in epidemiological 
trends of malaria is critical to move this task forward (175). In addition, a continuous trend of 
malaria reduction requires commitments of both donors and the communities, a well-prepared 
plan to prioritize the limited resources as well as a functioning global cooperation (176, 177). 
Figure 7: From control to elimination. Source: WHO, Global action plan for a malaria free world (18) 
 
2.3.1 Effective coverage 
The effective coverage i.e. “the proportion of the population in need of an intervention who 
are using an effective intervention that is affected by both access and adherence to the 
intervention” (178-180) is an important factor in the process of reaching malaria elimination.  
Feasibility of this process requires development of effective tools accessible to and adhered 
by the population at risk. Adherence to the control measures depends on social, cultural and 
economical factors. Therefore delivery of the control measures to the population at risk must 
be combined with provision of information to and training of both community members as 
well as the health workers. There are various factors influencing the accessibility to malaria 
control measures such as the health system in general and its infrastructure in the region as 
well as current distribution strategies of the control tools. The distribution of the control 
measures is often not equitable. It has been shown that 20% of the poorest people at risk of 
malaria carry 58% of the total malaria burden and they tend to have less access to the control 
measures (178, 181, 182). 
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3 ZANZIBAR 
Figure 8: Map of Tanzania and Zanzibar 
  
Source: Wikipedia (251)  
All studies included in this thesis were conducted in Zanzibar, Tanzania. Zanzibar 
archipelago is located ca. 50 kilometres off the coast of Tanzanian mainland. This semi-
autonomous region consists of two main islands of Unguja and Pemba covering and area of 
2,461 km2  (183). 
3.1 CLIMATE 
Located just south of the Equator, the climate of Zanzibar is tropical and humid. The seasons 
are defined mostly according to rainfall, one long rain period in April-June and one short rain 
period in October-November. The period between July and September is the dry, cool season 
while the period between December and March is the dry, hot season.  
The total population of Zanzibar in 2012 was 1.3 million of whom the majority (60%) is rural 
and 64% of the population live in Unguja. The population density in Zanzibar is 530 per km2 
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and the life expectancy at birth is estimated to 60 years. The literacy rate is around 70%. The 
annual growth rate in Zanzibar is 2.8% and children make 13% of the total population. HIV 
prevalence in Zanzibar is around 1% (184). 
For years, Zanzibar was the centre for the Swahili culture. Swahili, originated from the 
Arabic word “Sahil”, the coast, is the language spoken in Zanzibar and in the costal regions is 
East Africa from south Somalia to north Mozambique as well as in Kenya, Tanzania, 
Uganda, Rwanda, Burundi and Eastern parts of the Democratic Republic of Congo. Often 
called the spice island, Zanzibar is one of the main locations for clove production. Zanzibar 
was a Sultanate for a long period. The name Zanzibar comes from the Arabic word of 
(Zinjibar =the land of the slaves) as for a long period of time, until late 19th century, Zanzibar 
was one of the several centres for slave trade in and around Africa. Between late 19th century 
and 1964, Zanzibar was a British protectorate but after the 1964 revolution, Zanzibar joined 
with the Tanganyika republic to form the United Republic of Tanzania. Zanzibar has its own 
government and parliament and is responsible for all non-union issues such as health care 
system.  
Zanzibar consists of ten districts (four in Pemba island and six in Unguja Island). Each 
district is divided to constituencies and then subdivided into shehias that are the smallest 
administrative unit in Zanzibar (185). Subsistence farming, especially food crops, is the main 
source of income to most of the inhabitants. Fishing and tourism contribute to the people’s 
income.  In recent years the real gross domestic product has grown (to ca. 7.0% in 2012). Yet, 
Zanzibar is still a low-income region. In 2012 the per capita income was US$ 638 per year 
i.e. <2 USD/day (186). 
3.2 HEALTH SYSTEM IN ZANZIBAR 
The health system in Zanzibar is divided between private and public health care systems. 
Private health care facilities and hospitals are mainly concentrated in the urban parts of 
Zanzibar (mainly Unguja). Major health services are however provided by the public health 
sector. Three levels of public health care facilities in Zanzibar are:  
• Primary level: Divided into primary health care units and centres (PHCUs and 
PHCCs)  
• Secondary level: Four district hospitals (all located in Pemba)  
• Tertiary level: The main referral hospital in Stone town (Unguja) 
Throughout Zanzibar, there are 134 PHCUs providing basic outpatient care with no 
laboratory services. Malaria is mainly diagnosed with RDT. PHCCs include basic laboratory 
services such as microscopy for malaria diagnosis as well as in-patient care. More than 95% 
of the population of Zanzibar live within five-kilometre distance from a public health facility 
(187). The under-five child mortality rate has decreased from 141 per 1000 live births in 2002 
to 73 in 2010 (188, 189). Improved breastfeeding practices, IMCI and high immunization 
coverage as well as the recent years’ dramatic reduction of malaria incidence are the main 
reasons for this significant reduction of the under-five child mortality (212, 252).   
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3.3 MALARIA IN ZANZIBAR 
Malaria has for a long time been one of the major burdens on the health system of Zanzibar. 
Until recently, Zanzibar was considered to be a typically malaria high endemic area. WHO 
started an eradication program in the late 1950’s. Malaria eradication in Zanzibar was not 
achieved but after reorganization of malaria eradication program in 1967, it succeeded in 
reducing the malaria prevalence significantly. In 1968, malaria was not considered a health 
problem in Zanzibar and the program was subsequently abandoned. Malaria prevalence in 
Zanzibar increased immediately following the development of P. falciparum resistance to 
chloroquine, vector resistance to DDT and technical and logistical difficulties. By the mid 
1990’s one third of all deaths at the hospitals (approximately 3300 deaths annually) were 
attributed to malaria (190, 191).  In 2001 malaria accounted for 41% of all diagnosis in health 
facilities and was ranked number one cause of morbidity and mortality in Zanzibar (253).  
After launching the combined malaria control strategies by RBM and WHO, Zanzibar started 
its attempt to control malaria in the beginning of the 21st century through deployment of 
control measures shown in Table 1.  
Zanzibar was among the first regions in Africa that deployed ACT for malaria treatment. The 
Zanzibar Ministry of Health and Social Welfare (after 2010 the ministry of health became an 
independent ministry (MoH)) changed its malaria treatment guidelines and deployed ACT as 
first line therapy instead of chloroquine in 2002. This policy was implemented in September 
2003. Short afterwards large-scale distribution of ITN and later LLIN as well as biannual IRS 
treatment of interior walls of the houses of Zanzibar started. The impact of deployment of 
ACT and LLIN resulted in a significant reduction of malaria morbidity and mortality within 
three years of deployment of ACTs and later LLIN (3, 192, 193).  
Paracheck® RDT for P. falciparum malaria diagnosis was first introduced in some parts of 
Zanzibar by the non-governmental organisation Médecins Sans Frontières (MSF) in the mid 
2000s (56). By 2007, RDT was deployed in all PHCUs where BS microscopy was not 
available. In 2008 the diagnostic criteria for malaria was changed to confirmation by either 
RDT or BS microscopy. The previously widely used diagnostic criteria of so-called “clinical 
malaria” were removed from the health management information system (192, 193). Malaria 
RDT was in 2009 incorporated in the Zanzibar version of (IMCI) guidelines (193). Later, in 
2011, Paracheck® RDT was replaced with SD-Bioline Malaria Ag P.f/Pan which enables 
detection of other malaria species than P. falciparum alone.  
In 2008, the Malaria Early Epidemic Detection System (MEEDS), a system for reporting 
malaria cases electronically through mobile phones on weekly basis was established. 
Following further decline of malaria cases, Malaria Case Notification (MCN), for follow-up 
of all malaria cases, testing and treatment of household contacts and provision of preventive 
interventions and health information was introduced in 2012 (194).  
By 2012, the parasitologically confirmed (with BS microscopy or RDT) malaria positivity 
rate in all age groups was <1% and in August 2013, Zanzibar Malaria Control Programme 
(ZMCP) changed its name to Zanzibar Malaria Elimination Programme (ZAMEP) marking 
the entrance of the new phase of approaching malaria elimination in Zanzibar.   
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Table 1: malaria control interventions in Zanzibar 2002-2012 
Year Interventions 
2002 Introduction of ACT as the first line malaria treatment at all public health care facilities in 
Zanzibar. 
2003 Implementation of the ACT at all public health centres in Zanzibar, free of charge, in September 
2003.  
1st line treatment: Amodiaquine + Artesunate (Aq-As). 
2nd line treatment: Artemether – Lumefantrine (Co-artem®).  
3rd line treatment: Quinine and the drug of choice for severe malaria.  
(SP) for (IPT) in pregnancy as well as uncomplicated malaria in pregnant women. 
2004 Initial distribution of ITNs by ZMCP and through schools and community leaders, free of 
charge. 
2005 Overall distribution of LLIN to children under five and pregnant women. 
2006 First round of IRS in July 2006. 
Implementation of RDT at some peripheral health centres. 
2007 Wide scale use of RDT at the peripheral health facilities for malaria diagnosis. 2nd and 3rd 
rounds of IRS. 
2008 4th round of IRS, (universal distribution of LLIN i.e. 2 nets per households). 
 Introduction of MEEDS 
2009 New treatment guidelines for second line malaria treatment (222). 
1st line treatment: Amodiaquine + Artesunate  
2nd line treatment: Quinine 
3rd line treatment: Parenteral Quinine 
SP for IPTp 
Uncomplicated malaria in the first trimester oral Quinine, in the second and third trimester 
(ACT). 
2010 5th round of IRS 
2011 Deployment of combined HRP-2 and pLDH (SD-Bioline Malaria Ag P.f/Pan) RDT for 
detection of both P. falciparum and mixed malaria infections. 
2012 LLIN distribution (two nets per household) 
IRS policy change – from universal to focal targeting hotspots (carbamate) 
Introduction of MNC and household screening  
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4 RATIONAL FOR THE DOCTORAL PROJECT 
This thesis consists of two parts. Part one (study I and II) describes the prospects of the 
feasibility of achieving malaria elimination in Zanzibar following the implementation of 
malaria control interventions and the assessment of the effective coverage of these 
intervention after the significant reduction of malaria transmission in Zanzibar.  
Despite the recent years improvements, P. falciparum malaria still remains a major cause of 
death among small children in sub-Saharan Africa. Zanzibar has been among the first to 
implement the combined malaria control strategies by initiating deployment of ACT in 2003, 
mass distribution of LLINs and bi-annual IRS in 2006 and use of RDT for malaria diagnosis. 
After the initial reports of marked reduction of incidence of P. falciparum malaria the official 
goal of Zanzibar was set up to eliminate malaria on the isles.  
A successful transition from control via pre-elimination to elimination of malaria depends on 
three important factors of prevention, treatment and surveillance. However, considering 
Zanzibar to be a previously high endemic area in sub-Saharan Africa, the potential and 
feasibility of such a transition is to be studied. Zanzibar’s attempt to eliminate malaria 
provides unique research opportunities and challenges, particularly to assess the sustainability 
of the present achievement towards pre-elimination and further towards elimination as well as 
prevention of re-introduction (Study I). 
Sustaining a high coverage of vector control interventions is important for maintaining the 
state of low malaria prevalence and for further decline in malaria transmission as well as 
prevention of malaria resurgence. Zanzibar provides a unique research opportunity for 
assessment of sustained high effective coverage of vector control measures following the 
significant decline of malaria transmission in recent years (Study II). 
Part two (study III and IV) describes the efficiency of different malaria diagnosis tools in the 
new epidemiological context that emerged after rapid decline of malaria in Zanzibar 
including use of molecular tools for surveillance.  
Good malaria case management includes an effective and quality assured system for malaria 
case detection that ensures improved targeting of ACTs to patients with malaria infection. 
Overuse of the expensive ACTs will not only be a substantial financial burden on the health 
care system, but more importantly it will prevent other causes of fever (e.g. pneumonias 
which require antibiotics) from being appropriately treated.  
The usefulness of RDTs in the new malaria endemic context in Zanzibar including its 
performance within IMCI algorithm for childhood illness management needs to be assessed 
particularly with regards to adherence to test results as well as sensitivity and specificity as 
compared with detection of malaria parasites with BS microscopy and PCR (see below Study 
III and IV).  
We also investigate the field applicability of RDTs as a source of parasite DNA for DNA 
extraction for molecular surveillance. This underlines the potential of RDTs in modern 
malaria control, not only as a key diagnostic tool but also for molecular surveillance (Study 
IV). 
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5 AIMS AND OBJECTIVES 
5.1 OVERALL AIM 
To assess the effectiveness of malaria control tools and interventions for achieving malaria 
elimination in Zanzibar.  
5.1.1 Specific objectives 
• To assess the impact of combined malaria control interventions on malaria 
transmission in Zanzibar. 
 
• To assess effective coverage of malaria preventive measures following the significant 
reduction of malaria burden in Zanzibar. 
 
• To assess the efficiency of HRP-2 based RDT for P. falciparum case detection 
including its performance within the local version of the integrated management of 
childhood illness (IMCI) algorithm among febrile patients at first level health care 
facilities in the new context of low malaria transmission in Zanzibar and to evaluate 
the health workers’ adherence to the RDT results.  
 
• To compare and evaluate different methods of DNA extraction from RDTs for 
molecular surveillance.  
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6 STUDY SITES 
The studies included in this PhD project were conducted in two districts of Micheweni 
(Pemba island) and North A (Unguja Island) in Zanzibar (figure 8 and 9). These two districts 
are with regards to their demographic composition as well as malaria epidemiology 
considered to be representative for Zanzibar overall.  Both districts are mainly rural and have 
a population of about 100,000 each out of 1.3 million in Zanzibar. Both districts have access 
to one PHCC, which includes a hospital with out and inpatient care and laboratory 
equipment, including malaria microscopy service and blood transfusion facilities. Two 
private health facilities have been established in each district in recent years. Anopheles 
gambiae and Anopheles funestus are the main vectors.  
Following the mass distribution of LLIN and universal deployment of IRS in all households 
throughout the isle for vector control and introduction of ACT for malaria treatment, a 
significant reduction of malaria morbidity and mortality was achieved (3). With increasing 
coverage of malaria control measures a further decline of parasitologically confirmed malaria 
positivity rate was observed (187). 
Study III was a health facility based study, conducted in 12 primary health care facilities (one 
PHCC and five PHCU from both Micheweni and North A districts). Health facilities were 
selected with regards to their geographical distribution as well as the skilled cadre of conduct 
of the study. Zanzibar introduced RDTs for malaria diagnosis at PHCUs in 2006.  
6.1 ETHICAL CONSIDERATION AND CLINICAL TRIAL REGISTRATION 
All studies were conducted in line with the principles stated in the latest version of the 
Declaration of Helsinki and Good Clinical Practice (254, 255).  
Studies conducted in Zanzibar were approved by the Zanzibar Medical ethics committee 
previously known as The Zanzibar research Council, reference numbers: (ZHRC 
/RAP0/03/2004, ZAMEC 0001/09, ZAMEC/ST/0001/010, ZAMREC/0001/JUNE 011, 
ZAMREC/0001/APRIL/013) and the Regional Ethics Review Board, Stockholm, Sweden 
(Reference number: 2009/387-31).  
Ethical approval for molecular analysis conducted in Sweden was obtained from the Regional 
Ethics Review Board, Stockholm, Sweden, Reference number: (2009/387-31). 
Informed written consent from all study participants were obtained prior to their participation 
in the study. The consent was witnessed. For children, a proxy-consent from parents or their 
legal caretaker was received. Information meeting together with local leaders (Shehas) were 
held prior to start of each cross-sectional survey in order to inform the communities about the 
anticipated study. Clinical Trial registration on ClinicalTrials.gov for study II and IV with 
study identifier NCT01002066 was made (not applicable for study I and II).  
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Figure 9: study sites and shehias distribution in Micheweni and North A districts, Zanzibar. 
Source: ZMCP  
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7 PART ONE 
7.1 MATERIALS AND METHODS 
7.1.1 Study population sampling and data collection 
Study I 
This was a longitudinal, observational and multidisciplinary study conducted in both 
Micheweni and North A districts. Malariometric data including community parasite 
prevalence, health facility data, vital statistics and entomological data were obtained as 
following:. 
Cross sectional surveys conduced between 2003 and 2012, which included eight surveys 
(2003, 2005-2009, 2011 and 2013). Sampling methods are described under study I. Health 
facility data from 1999 to 2013 were collected from all 26 PHCUs and PHCCs in both 
districts. Vital statistics for North A district for the period of 1998 to 2012, were obtained 
from the District Commissioner’s Office in North A. A sub-study on risk factors for malaria 
infection included data collected in study III.  Monthly rainfall data between 1999 and 2012 
for North A and between 2005 and 2012 for Micheweni district were obtained from the 
official registers of the Zanzibar Office Division of the Tanzanian Meteorological Agency of 
the Ministry of Communication and Transport. 
Entomological data were collected from several sites on Unguja and Pemba islands from 
2005 onwards where mean human biting rates using the human-landing catch method were 
determined.  
Study II 
This study was conducted in two districts of Micheweni and North A. The sampling was 
done according to two-stage cluster sampling technique (195). Sampling units were the same 
randomly selected shehias used in the previous cross sectional studies. From each shehia 
households were randomly selected proportional to the size of the shehia. Assuming a 
proportion of 50% of children under five sleeping under bed-nets, and accounting for a 
cluster effect of two, a sample size of 192 children under five was needed to determine LLIN 
use with an absolute precision of ±10% and a 95% confidence interval (CI). Since the study 
was conducted in conjunction with the cross sectional survey of 2009, the total number of 
caretakers interviewed was 560 in total which was larger than required.  
7.1.2 Laboratory and molecular methodologies  
Study I 
Molecular analysis included DNA extraction and PCR analysis. Two PCR methods followed 
by restriction fragment length polymorphism (RFLP) analysis were used: cytochrome b 
(cytb) nested PCR (224) and cytb SYBR Green qPCR (Xu W et al., unpublished). Parasite 
density was estimated by qPCR. The molecular analyses are described further in part two 
under study III and IV 
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7.1.3 BS microscopy and RDT 
In all cross sectional surveys conducted between 2003 and 2009, thick BS for malaria 
diagnosis were collected from all study participants. All slides were stained with 5% giemsa 
staining and experienced microscopists conducted microscopy examination for P. falciparum 
parasite detection as well as determination of parasite densities. If less than ten parasites were 
detected per 200 WBCs, examinations were extended to 500 WBCs. Blood slides were 
considered negative if no asexual parasites were found in 200 high-power fields. Asexual 
parasite densities were calculated against 200 WBCs assuming 8,000 WBCs per µl of blood 
(70). Quality control (independent second reading) was done for all positive slides as well as 
10% of the negative slides. RDT replaced microscopy with a P. falciparum specific HRP-2-
based device (Paracheck-pf®) in 2011 and in 2013 a combo RDT detecting both HRP-2 and 
pan-Plasmodium lactate dehydrogenase (SD-Bioline Malaria Ag P.f/Pan) was used. 
7.1.4 Filter paper preparation  
In cross sectional studies conducted from 2005 and onwards, approximately 100 µl of blood 
(3-4 blood drops) was collected from all consented participants on FP (3MM Whatman) and 
then dried and stored according to standard procedures. After completion of the studies, 
samples were transported to Karolinska Institutet in Stockholm, Sweden for further 
laboratory analysis such as PCR technique for assessment of potential reservoir of low 
malaria parasitaemias and determination of molecular markers for drug resistance (127, 128, 
196) as well as malaria serology. 
7.1.5 Malaria serology 
The antimalarial antibody responses was assessed by enzyme-linked immunosorbent assay 
(ELISA) from blood spots collected during the cross sectional survey in 2009 on FPs as 
described above. The serology analysis was done as described previously (114, 197). The 
presence of immunoglobulin G antibodies against three P. falciparum blood stage proteins, 
apical membrane antigen-1, (PfAMA-1), glutamate rich protein (PfGLURP) and merozoite 
surface protein (PfMSP-1) was tested in all samples. Individuals were considered positive if 
they responded to one or more antigens. 
Study II 
Study II included no laboratory or molecular procedures. 
7.1.6 Data management and analysis 
Study I  
Data entry and validation were done by Microsoft Access and Microsoft Excel. Statistical 
analyses for cross-sectional surveys, health facility records, vital statistics, and rainfall data 
were performed using STATA 12 &13 software. Pearson correlation coefficients [rp] were 
calculated to assess the linear relationships between monthly rainfall and outpatient 
confirmed malaria incidence and a Poisson regression model were used to assess the effect on 
malaria incidence and the interaction between age (categorized as <5 and >5 years of age) 
and calendar year. 
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Malaria serology data were analysed using sero-conversion rate (SCR) to estimate the force 
of infection i.e. “incident malaria cases per unit of population-time”. This was done by 
adjustment to a “simple reversible catalytic model” to the measured sero-prevalence, 
stratified into yearly age groups by using “maximum likelihood methods” (198). Temporal 
change in SCR was identified using profile likelihood plots and likelihood ratio tests 
against models with no change (197, 199). 
Study II 
Data entry was conducted using CSPro program, thereafter the data was transferred into 
Excel for data cleaning and coding of the open-ended questions.  The data were then 
imported into STATA software where open-ended answers were coded into different 
categories (ex. Age and years of education were re-coded into categorical variables). Data 
analysis was conducted using STATA 10 software. These included univariate analysis 
(means and medians of continuous variables or frequencies and proportion of categorical 
variables), bivariate analysis (chi-square test or logistic regression ex. the factors associated 
the use of LLIN among children under five) and multivariate analysis (all variables that were 
at the significance level of p ≤ 0.25 in the bivariate analysis). Adjusting the p-value for cluster 
effect on the shehia level was done. Equity analysis was done to determine the weights for an 
index of the asset variables (200).  The study population was hence categorized into socio-
economic quintiles based on an asset index based on type of floor, walls and roof, source of 
water and light, type of toilet and cooking facilities, and owning 20 different possessions such 
as bicycle or radio. Effective coverage of LLIN and IRS in children under five belonging to 
different socio-economic quintiles was then compared. The significance of the outcomes was 
analysed using logistic regression.  
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7.2 RESULTS 
Study I 
Table 2: Number of households Surveyed, age and sex of the cross sectional studies’ participants in 
Micheweni and North A districts (2003, 2005-2009, 2011 and 2013) 
a) Micheweni 
Year 03 05 06 07 08 09 11 13 
HH, n 550  397  397  448  3493  499  488 427 
<5 476  283  323  395  19209  476  312  399 
5-14 222  323  301  420  36083  222  417  820 
>14 982  889  952  1180  ND  982  761 1191 
Female % 45% 48 %  54 % 50 %  49 %  51 %  57 % 51% 
b) North A 
Year 03 05 06 07 08 09 11 13 
HH, n 621  474  483  517  3477  498  528 401 
<5 677  314  320  375  15735  281  358  333 
5-14 601  441  386  387  28897  220  427  618 
>14 1535  1189  1151  1124  ND  888  886  1073 
Female % 51 % 48 % 50 % 51 % 50 % 52 % 60 % 54 % 
7.2.1 Intervention uptake 
After the mass distribution of LLIN in early 2006 the reported proportions of people sleeping 
under ITN/LLIN according to the cross sectional surveys conducted between 2006 and 2013 
increased by 61% and 34% to 70% and 71% in Micheweni and North A, respectively.   
However, children under five were significantly more likely to use ITN/LLIN (78%) than 
individuals ≥5 years (62%). From 2008 to 2012 the proportion of households reporting 
having had IRS within the last year was over 85% in both districts. 
ACTs were available in all PHCCs without any documented stock-out period since their 
implementation in late 2003.  
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7.2.2 Community parasite prevalences and serology 
Figure 10 shows the overall P. falciparum parasitaemia of all ages at the time of cross-
sectional surveys in both districts of Micheweni and North A determined by BS microscopy 
or RDT and in relation to malaria control interventions. 
Between 2003 and 2013 a mean reduction of 97.0% of P. falciparum parasitaemia was 
observed. The main reduction in parasite prevalence occurred during 2006 and 2007 after the 
introduction of LLINs and IRS. Thereafter prevalences were maintained around 0.4% in 
Micheweni and 0.2% in North A.  
In 2013, the PCR determined community parasite prevalences were 2.7% in Micheweni and 
1.8% in North A (mean 2.3%, 95% CI 1.8-2.8). This represents a mean reduction of 89.0% as 
compared with 2005. 
Malaria seroprevalence and force of infection 
Serological analysis of samples from 2009 showed an increase in malaria seroprevalence with 
age. The overall seroprevalence was 37.4% (595/1598) in Micheweni and 19.3% (238/1232) 
in North A. Profile likelihood analysis identified distinct changes in SCRs at 5 years of age 
(i.e. after 2004) in both districts. SCR values indicated approximately 3-fold reduction in 
exposure in Micheweni and 5-fold reduction in North A comparing pre- and post-intervention 
initiation periods. 
Figure 10: Malaria parasitaemia detected with BS microscopy or RDT in cross sectional surveys (2003-
2013) in Micheweni and North A Districts combined, Zanzibar 
 
 
2003 2005 2006 2007 2008 2009 2011 2013 
pos rate <5 12,7% 12,2% 4,2% 0,9% 0,6% 0,0% 0,3% 0,1% 
pos rate 5-14 18,0% 9,9% 4,2% 0,7% 0,7% 0,0% 0,5% 0,3% 
pos rate >15 Y 4,4% 2,5% 0,8% 0,1% 0,2% 0,0% 0,4% 0,2% 
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7.2.3 Health facility data 
Following the introduction of RDT, the mean malaria-testing rates of all outpatients between 
1999 and 2005 in Micheweni and North between 2006 and 2012 increased from 11% and 7% 
to 22% and 24%, respectively.   
The parasitologically confirmed outpatient malaria diagnoses reported between January 1999 
and December 2012 are presented by month in Figure 11 (a and b). The overall mean 
reduction in blood slide/RDT positivity rate between 2002 and 2012 was 96.0% in the two 
districts. Similarly to the trends in community based parasite prevalences, the main reduction 
occurred after September 2005 when vector control was implemented in addition to ACT. 
From 2008 onwards relatively steady blood slide/RDT positivity rates were observed with 
averages of 1.9% in Micheweni and 0.8% in North A.  
7.2.4 Rainfall and malaria 
No major changes in the annual rainfall were observed in North A between 1999 and 2012, 
except for 2003 and 2010 (Figure 11, a and b). The mean annual rainfalls for these two years 
were 42% and 20% lower than the mean annual rainfall (1219 mm) for the remaining years 
but this had no influence on the confirmed malaria positivity rates among fever patients. A 
significant correlation was however observed between monthly rainfalls and confirmed 
malaria diagnoses between 2007 and 2012 ( [rp] =0.37, p<0.01), whereas no such correlation 
was observed during the pre-intervention and early malaria intervention periods (1999-2002 
and 2003-2006) ([rp] =0.04, p=0.78 and [rp] = 0.33, p=0.11).   
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Figure 11: Positivity rates (confirmed malaria infection/total number of tested) among <5 and ≥5 febrile 
patients in public health care facilities in relation to monthly rainfall and introduction of ACT, LLIN and 
IRS in a) Micheweni and b) North A district between 1999 and 2012.  
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7.2.5 Crude child mortality  
Figure 12 shows decline of all cause mortality figures among children under five by 70% in 
North A district between 1998 and 2012. The observed decrease was most pronounced in 
children aged 1-4 years with a reduction from an average of 64 to 14 reported deaths per year 
between 1998-2002 and 2007-2012, equivalent to a 78% reduction in absolute numbers. For 
children <1 year the corresponding reduction was 60% from 86 to 34 deaths. 
Figure 12: Crude under-five, infant (<1y) and 1-4 y mortality between 1998 and 2012 in North A district  
 
7.2.6 Entomological findings 
Between 2005 and 2012, the strengthened vector control was associated with 99% reduction 
of the human biting rate (HBR). Generally, in recent years, there has been an increasingly 
marked seasonality with over 80% of mosquitoes collected during the three months of rainy 
season. We also observed a relative shift towards outdoor biting An. arabiences becoming the 
predominant malaria vector.    
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Study II 
7.2.7 Vector control coverage 
The overall ITN use among children under five in Zanzibar in 2005 was at 40%. Use of ITN 
among children under five in Micheweni district was only 10% which was the lowest rate in 
Zanzibar. Following the previously described LLIN mass distribution campaigns in Zanzibar, 
the bed net coverage among under- five children increased as shown in table 3. No 
statistically significant difference in LLIN usage between Micheweni district (218/322 
(68%)) and North A district (241/338 (71%))  (p = 0.45) was found.  
IRS coverage was higher than bed-net coverage; while 85% (503/660) of all children under 
five were reported to have slept under a treated bed net the night before the survey, effective 
IRS coverage of the children under five was 95% (638/675). 
Equity analysis showed a similar effective coverage of LLIN in the poorest income group 
(70%) and the least poor (69%) but a tendency of a higher effective coverage of IRS in the 
least poor (99%) compared with the poorest (93%) was seen, however the difference was not 
statistically significant (p = 0.055) 
Twenty-five per cent (125/508) of the caretakers reported seasonal use of bed-nets by their 
under-five children.  
Table 3: Effective coverage of vector control intervention among children under five in Micheweni and 
North A district  
Vector control intervention Micheweni North A Total 
Bed net (ITN or LLIN)  236/322 (73%) 267/338 (79%) 503/660 (85%) 
IRS 314/333 (94%) 324/342 (95%) 638/675 (95%) 
At least one of the 
interventions (IRS or bed net) 
307/314 (98%) 321/339 (98%) 628/643(98%) 
7.2.8 Caretakers’ perceptions on malaria and vector control tools 
Eighty-seven percent of the caretakers felt that the malaria burden had been declined 
compared to five years before and many of them (66%) did not see malaria as a serious health 
problem. Nevertheless, 83% of caretakers viewed children to be the age group most at risk of 
malaria infection.  
Use of bed-nets and IRS was mentioned by 41% and 31% of the caretakers as the reason for 
the decline of malaria burden. Most caretakers (74%) viewed bed-nets as the best tool for 
preventing malaria.  The best advantage of IRS was believed to be mosquito and general 
insect reduction. A minority (20%) of the caretakers mentioned side effects of IRS such as 
itching and increased mosquito and insect populations (such as bed bugs). 
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7.2.9 Sustainability  
A vast majority of the caretakers (95%) said that they would continue to use malaria 
preventive measures for their under-five children. Ninety-three per cent recognized the 
significance of continuing bed net use and 89% of caretakers also stated the importance of 
continues use of IRS.  
7.3 DISCUSSION  
A major decline in malaria transmission in Zanzibar following intensified malaria control 
interventions was observed. This was most pronounced from 2004 to 2007 whereafter a 
persistent low-level transmission with seasonal increases emerged. The most significant 
impact on malaria prevalence and incidence was achieved after the intensified vector control 
with LLIN and IRS whereas the reduction of crude mortality was observed after the 
introduction of ACT.  
7.3.1 Sustainability of high effective coverage of malaria control 
interventions 
Overall good accesss to public health care as well as a continuous supply and adherence to 
RDTs and ACTs (56, 201, 202) have supported a continued efficient management of clinical 
malaria episodes in all age groups in Zanzibar. 
Both studies (I & II) confirm a high and equitable effective coverage of and adherence to 
vector control measures (LLIN and IRS) in both districts following free mass distribution of 
bed net and IRS campaigns. 
Maintained access to bed net for reaching high effective coverage is a challenge. Three mass-
distribution campaigns in Zanzibar (2006, 2009 and 2012) have resulted in a sustained and 
relative high effective coverage of bed-nets. Both studies show that children under five use 
ITN/LLIN more than individual ≥5 years but the use of ITN/LLIN in all age groups in 
Micheweni and North A was still relatively high (around 70% between 2006 and 2013). This 
should be seen with regards to the assessment report on the feasibility of malaria elimination 
in Zanzibar which due to Zanzibar’s high transmission potential and outbreak risk 
recommends an effective coverage of LLINs of at least 75% for reaching malaria elimination 
within a decade (203).  
Our findings in study II show that the dramatic decline of malaria in Zanzibar was well 
understood by the caretakers. However, the caretakers’ low malaria risk perception did not 
influence their use of LLIN negatively as was previously suggested in other studies in 
Vanuatu (204-206). The caretakers highly appreciated LLIN as a malaria prevention method. 
The coverage of IRS was higher than that of bed-nets, but IRS was a little less acknowledged 
for malaria prevention compared to LLIN. There were also some caretakers who mentioned 
few disadvantages of the IRS such as itching, and increase of insects which has also been 
reported from another study where DDT was used for IRS (207). Factors influencing 
community members to adhere to these interventions remain unclear. However, sustained 
high coverage of vector control tools is an important element of avoiding malaria resurgence 
and further reaching malaria elimination in Zanzibar. Access to these intervention measures is 
possible by maintaining their effective delivery by the government. Both studies show that 
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ZAMEP has achieved a sustained high effective coverage of malaria control interventions by 
a strong commitment of the Government of Zanzibar and external donors as well as high 
degree of community acceptance and involvement. 
7.3.2 The impact of combined malaria control measures on malaria 
epidemiology 
Following the deployment of the malaria control interventions in Zanzibar a significant 
reduction of malaria prevalence, confirmed malaria cases and crude under-five child 
mortality was observed. During the past recent years, significant reduction of malaria burden 
in several countries in sub-Saharan Africa has been reported (Table 4). However, the overall 
reductions in these areas were often less pronounced than in Zanzibar. There may be several 
reasons for this but we believe a main difference is the higher population-level uptake of the 
interventions in Zanzibar. Interestingly, there is a recent report of similar reduction of malaria 
transmission in a village in Senegal as in Zanzibar after apparent high access to preventive 
and curative interventions (8).  
Using PCR for parasite detection in the cross sectional surveys, revealed a major reservoir of 
low-density asymptomatic parasitaemias across all age groups. Similar results have been seen 
in other low malaria transmission areas (108, 208, 209). An important impact of these low-
density parasitaemias is that they may contribute significantly to the residual on-going 
transmission (108, 210, 211). 
Our study provides data on a significant reduction of all cause child mortality coherent with 
the timing of the introduction of ACT. A similar decrease in crude child mortality was also 
observed on Bioko Island after massive malaria control interventions (213).  However, in 
addition to the dramatic decline of malaria transmission in Zanzibar, other factors such as 
improved breastfeeding practices, IMCI, high immunization coverage and some improvement 
of the economical situation in Zanzibar cannot be fully ruled out (186, 189, 212). The strong 
impact on mortality may be explained by the reduced number of severe malaria episodes 
(following general improvement of malaria case management) but also by general reduction 
of malaria infections being a risk factor for severe manifestations of other accompanying 
bacterial infections, e.g. septicaemia (214, 215). 
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Table 4: Reported impact of different malaria control interventions in several different regions in Africa 
(2006-2014) 
Country 
/setting 
Observation 
period  
Methods Malaria control interventions Outcome(s) 
Five health 
facilities in 
different 
regions in The 
Gambia 
1999-2007 Retrospective 
analysis of health 
facility records 
Three fold increase in the 
proportion of children sleeping 
under ITN 
Malaria treatment with ACT 
(free of charge) 
SPR declined by 73% 
MAD reduced by 100% 
MA reduced by 74% 
Zambia 2003-2008 Program 
evaluation using 
different data 
sources such as 
national surveys, 
special studies 
and in-country 
reports 
Sleeping under ITN increased by 
75% 
No. of HH sprayed with IRS 
increased by 66%  
Use of ACT for malaria 
treatment 
53% reduction of SPR and 68% 
reduction of severe anaemia in 
children under five. 
Mortality in infants and children 
aged 1-4 years decreased by 
38% and 36%, respectively 
Kilifi (Kenya) 1990-2007 Retrospective 
analysis of 
hospital data 
Replacement of chloroquine with 
SP in 1998 and later with ACT in 
2006 for malaria treatment (free 
of charge). The bed net coverage 
per person was doubled. 
16-fold reduction of malaria 
prevalence. MA and MAD 
declined by 80%  
Dielmo 
village 
(Senegal) 
2007-2010 Longitudinal 
monitoring of 
inhabitants 
Distribution of LLIN among 
inhabitants where no LLIN was 
used before. 
Use of ACT for malaria 
treatment 
Malaria incidence decreased 
from 5.45 per 100 person-
months to 0.41 but increased 
back to 4.57 due to development 
of vector resistance against 
pyrethroid.  
30 district 
hospitals in 
Rwanda 
2005-2010 Retrospective 
analysis of 
hospital and 
program data 
Sleeping under ITN increased 
from near zero to 76% 
ACT deployment for malaria 
treatment 
Over 50% decline in SPR, MA 
and MAD  
Two villages 
in North east 
Tanzania 
2003-2008 Annual cross 
sectional surveys 
Training village health workers 
in malaria case management  
Proportion of people sleeping 
under ITN in both sides reached 
to  >60% 
Malaria prevalence reduction by 
ca. 85% 
Several 
regions in 
Ethiopia and 
Rwanda 
2001-2007 Retrospective 
analysis of health 
facility data 
Large scale distribution of LLIN 
and use of ACT for malaria 
treatment 
 
MA and MAD reduction in 
children under five by 55% and 
67% in Rwanda and by 73% and 
62% in Ethiopia, respectively 
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São Tomé e 
Príncipe 
2005-2007 Retrospective 
analysis of health 
facility data and 
malariometric 
surveys conducted 
by the CNE 
IRS  
Free distribution of LLIN 
Use of ACT for malaria 
treatment and SP for IPTp. 
MA and MAD reduction by 
80% and 95% respectively. 
Malaria prevalence reduction by 
93% 
The Bioko 
Island 
(Equatorial 
Guinea) 
2003-2005 Household 
surveys and 
retrospective 
analysis of data 
from one health 
facility 
IRS  (86% of surveyed 
household were sprayed with 
IRS) 
IPTp 
Malaria prevalence and 
confirmed malaria cases reduced 
by 32% and 14% respectively 
 
Zanzibar 
(Study I) 
 
1999-2013 Temporal trends 
of different 
malariometric 
indices in two 
districts with a 
population of 
approximately 
200.000 people  
Sleeping under LLIN increased 
by 22% and 61% in respective 
district to 70% 
85% of all HH were sprayed 
with IRS 
Use of ACT free of charge & SP 
for IPTp 
Malaria prevalence reduced by 
97% 
Confirmed malaria cases 
reduced by 95% 
Reduction of the annual under- 
five mortality rate by 70%  
(4, 7, 9, 11-13, 158) 
(SPR= Slide positivity rate, MAD= Malaria attributed death, MA= Malaria admission, ACT= Artemisinin-based 
combination therapy, HH= Household, ITN= Insecticide treated bed net, LLIN= Long lasting insecticide treated 
nets, IRS= Indoor residual spraying, SP= Sulfadoxine-pyrimethamine, IPTp= Intermittent preventive treatment 
in pregnancy, RDT= Rapid diagnostic test, CNE= Centro National de Endemias) 
Our findings highlights the following important changes in malaria transmission following 
implementing malaria control strategies in Zanzibar:  
a) Malaria pre-elimination status was achieved already in 2007 after the rapid reduction 
of malaria transmission between 2004 and 2007 as described above.  
b) Malaria transmission has changed towards more seasonal transmission. In addition, a 
geographically more heterogeneous transmission where malaria cases are distributed 
unevenly in few identifiable hotspots has occurred (217). These hotspots may be a 
main driving force of the present malaria transmission (218).  
c) The annual parasitologically confirmed malaria positivity rate after 2008 has been 
fluctuating between 1% and 2% despite a sustained and relative high effective 
coverage of malaria control interventions.  
d) After 2008, an increased proportion of confirmed malaria cases were seen among 
patients above 5 years of age. A similar shift in age among PCR detected low-density 
parasitaemias was not found. Malaria immunity is expected to decline as transmission 
reduces. This may result in a relative increase of infections in age groups that were 
previously protected through repeated exposure. Additionally, older age groups 
remain outside in the evenings and use LLIN less than children under five and 
therefore they are exposed more to outdoor biting mosquitoes. A similar shift in age 
  53 
among clinical malaria episodes has been documented along with reduced 
transmission in Kenya (7). 
Recently, development of pyrethroid resistance was observed on Pemba Island (156). 
Moreover, all vector control measures are directed towards indoor biting/resting mosquitoes. 
Following wide scale use of LLINs In Zanzibar, like several areas of sub-Saharan Africa 
(151-154) a shift in anopheline species towards outdoor biting/resting mosquitoes (An. 
arabiensis) has been observed. Therefore, despite the major reduction of HBRs a major 
reason for a halt in reduced transmission may be attributed to this change in mosquito 
population. 
Finally, imported malaria from other areas in mainland has been mentioned as the main 
source for malaria transmission in Zanzibar based on modelling (219). In contrast to this 
report we believe that the bulk of the residual transmission appears still to take place within 
Zanzibar as travelling outside Zanzibar was reported by relatively few of malaria infected 
patients and can thus account for only a minor portion of the overall malaria incidence. Other 
malaria risk factors were not sleeping under LLINs or not having IRS recently performed. 
This suggests that transmission is still taking place indoors and promoted compliance to bed 
net use should still be required. 
Zanzibar has reached the state of low malaria transmission but low-density parasitaemias, 
entomological changes, malaria transmission hot spots as well as difficulties in increasing 
high effective coverage of vector control measures are among challenges Zanzibar is facing 
for further decline of malaria transmission. Introduction of active case detection i.e. “an 
immediate investigation of detected malaria cases at health facilities through visits to 
patients’ homes and screening of approximately 100 neighbouring households to identify 
additional cases” (203) and IRS (carbamate) specifically targeting identified hotspots as well 
as use of single dose primaquine (for additional reduction of gametocytes) together with ACT 
are some of the new efforts introduced in Zanzibar addressing the above mentioned 
challenges. In addition to an increased level of effective coverage of vector control measures; 
use of sensitive molecular diagnostics for mass screen and targeted mass drug administration 
including seasonal malaria chemoprevention especially with regards to hot spots and risk 
groups are among other important actions needed for reaching malaria elimination (220, 221). 
As existing interventions will largely have to be maintained and new interventions must be 
added, an even greater need of financial support for avoiding malaria resurgence and to reach 
a malaria free Zanzibar is crucial. 
7.4 LIMITATIONS 
Study I 
Unlike other malariometric data we could not triangulate morality data with data from other 
sources. In the past decade a general reduction of child mortality in Sub-Saharan Africa and 
Tanzania in particular has been observed. Nevertheless, the decline of child mortality in 
North A was coincided with the introduction of ACT. Furthermore, there are other studies 
that have shown the correlation between reduction of malaria burden and reduced child 
mortality. 
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The study was conducted in two districts of Zanzibar covering 20% of the whole population. 
Although there are differences in demography and socioeconomic condition between 
different parts of Zanzibar, the two district can be seen as representative of the isles with 
regards to the demography, climate, distribution of health services and so on.  
Finally we did not have access to rainfall data between 1998 and 2005 in Micheweni; neither 
did we have vital statistic data from this district.  
Study II 
Use and wish to use malaria prevention measures may have been overestimated due to 
“desirability bias”. This bias may have been increased due to the fact that the survey was 
identified with the ZMCP and the interviewers were health professionals. However, in order 
to minimize this risk, the importance of creating a comfortable environment during the 
interview was emphesized. Moreover, results from other studies indicate a similar and even 
higher rate of use of LLIN enhancing the validity of the findings in this study (201 and study 
I).  
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8 PART TWO 
8.1 MATERIALS AND METHODS 
8.1.1 Study population sampling and data collection 
Study III 
We enrolled 3890 patients from 12 primary health care facilities in Micheweni and North A 
districts between of May-July 2010. The process of patients’ enrolment and study flow chart 
is shown in figure 13.  
Figure 13: Study flow chart 
 
(BS=blood smear, FP=filter paper, PCR=polymerase chain reaction) 
 
Adherence to RDT results was the primary endpoint and the base for sample size calculation. 
Based on the previous study in Zanzibar, we assumed that approximately 10% of the RDT 
negative patients are prescribed ACT (56). Considering a potential clustering effect on health 
facility level we calculated that a sample of minimum 3054 patients would allow for an intra-
cluster coefficient of slightly over 0.01 and still fulfil the given level of precision. 
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The participants in this study included patients aged ≥ 2 month, with fever (axillary 
temperature ≥ 37.5°C or history of fever during the preceding 24 hours) and who did not have 
symptoms of severe disease. Enrolled patients were tested with RDT. All RDT positive 
patients and randomly selected 20% of all RDT negative patients were additionally tested for 
malaria microscopy (thick BS). Further, approximately 100 µl blood on filter paper 
(Whatmann 3 MM) for additional molecular analysis were collected from these patients. All 
children under five were managed according to the IMCI guidelines. Malaria management 
was carried out according to the latest national treatment guidelines (222). Antibiotics and 
antipyretic medicines as well as other essential drugs (among children under five essential 
drugs were according to IMCI) were provided to all patients free of charge. Participation in 
this study included only one visit with no active follow up, however patients were 
encouraged by health workers to come back if there was no improvement of their condition 
or if their condition was deteriorated. Follow-up visit for children under five was 
recommended in accordance to the IMCI guidelines.  
Upon enrolment in the study basic demographic data, previous anti-malarial treatment (in 
case of pregnancy use of IPTp), use of treated bed net (ITN/LLIN) the night before the survey 
as well as travel history was registered.  
Study IV 
The samples used in this study (RDTs and FPs) were all collected among febrile patients who 
were enrolled in study III. 
8.1.2 Laboratory and molecular methodologies  
Study III 
8.1.2.1 RDT 
Malaria diagnosis was done using the HRP-2 based Paracheck-pf® RDTs (Orchid 
Biomedical Systems, Goa India) which by the time of the study was the RDT device 
deployed by ZMCP.  Performance and interpretation of the test was done in accordance to the 
manufacturer’s instruction.  
8.1.2.2 BS microscopy 
Preparation of the BS was done on site as descried in part one. Discordancy in BS results 
between the two readers (positive versus negative, difference in species diagnosis or a 
difference of 50% in parasite density), were sent to Karolinska Institutet, Stockholm, Sweden 
for re-examination by a third expert microscopist. This was applied to all BS from patients 
with discrepancies between RDT and PCR results, RDT and BS results or PCR and BS 
results. 
8.1.2.3 FP 
Approximately 100 µL of blood was collected on filter papers (Whatmann 3 MM). These 
were dried thoroughly, put in individual zipped plastic bags containing desiccant and stored 
in room temperature (ca. 25° C) in Zanzibar. After completion of the study, all samples were 
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transported to Sweden for further molecular analysis.   
8.1.2.4 DNA extraction 
DNA was extracted from three (Ø 3 mm) filter paper punches (equivalent to ca. 10-15 µl 
whole blood) from all filter papers using a modified version of the ABI 6100 Nucleic Acid 
Prep Station protocol (Applied Biosystems, Fresno, CA) (223). When there were 
discrepancies between RDT and PCR results, we used Chelex-100 method for DNA re-
extraction (224).  
8.1.2.5 PCR 
Samples belonging to all 121 RDT positive samples were analysed using P. falciparum 
specific nested PCR-Restriction Fragmental Length Polymorphism (RFLP) for detection of 
the following SNPs on specific drug resistance markers in P. falciparum parasites: N86Y, 
Y184F and D1246Y (pfmdr1) and: K76T (pfcrt) (128, 225, 226). Blood samples from all 733 
RDT negative patients were pooled two by two where presence of Plasmodium DNA was 
screened with 18S ribosomal DNA (found in all five Plasmodium species) real-time PCR. A 
cut-off of 42 cycles was used to determine positive samples which were selected for species 
identification (227). Samples with discrepant RDT and PCR results were once again analysed 
using nested PCR analysis targeting Plasmodium cytochrome b (224). 
Any PCR positive case which positivity was confirmed by another PCR method or by 
parasite detection by microscopy was defined as PCR positive. PCR analysis for HRP-2 
deletion was made for all negative RDT samples with positive BS and/or PCR (228).  
Study IV 
8.1.2.6 RDT 
For the purpose of DNA extraction from the RDTs, we compared DNA extraction from 
RDTs used in study III Paracheck-Pf® with Pf HRP-2/pan-LDH based RDT, SD-bioline 
Malaria Ag P.f/Pan (Standard diagnostic, Inc, USA) which is the RDT product used in 
Zanzibar since 2011that detects P. falciparum as well as non falciparum infections and mixed 
infections caused by both P. falciparum and other species.  
8.1.2.7 Preparation of Plasmodium falciparum in vitro samples  
In order to compare the detection limit of parasite DNA extracted from the two different RDT 
devices and FP samples, serial dilution of in-vitro cultured P. falciparum parasites was 
prepared. The parasite concentration in the culture was estimated by microscopical 
examination of giemsa stained thin films. Parasite cultures and malaria negative whole blood 
were lysed by freeze-thawing prior to serial dilution with parasite cultures and malaria 
negative whole blood.  
8.1.2.8 DNA extraction 
For the purpose of DNA extraction, the two RDT brands, were seeded with 5 µL blood of 
parasite concentration from 200,000 to 0,02/ µL which were derived from serial dilution as 
described above.  
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For comparison, FP was seeded in parallel with 5 µL (approximately equivalent to one 3-mm 
punch from the FP) of the serial dilutions. Before the extraction DNA cassettes were opened 
using a metal scapula and the nitrocellulose strip was into 3 mm pieces using scissors. DNA 
was then extracted from the distal two-third nitrocellulose strip of the RDTs containing 
approximately 5µL blood. Three different DNA extraction methods were evaluated  
1) Simple elusion method (102) 
2) Chelex-100 (229)  
3) A modified version of extraction of ABI-6100 protocol (223)  
DNA extraction from field samples were made from paired RDT and FP using the ABI 
PRISM 6100 Nucleic Acid PrepStation™ method. 
8.1.2.9 PCR 
All PCRs were run in parallel on DNA extracted from RDT and filter paper. PCR analyses 
for field samples were done using the PCR methods described in study III. Evaluation of the 
P. falciparum DNA extraction methods from RDTs and FPs was conducted by analysis of P. 
falciparum detection limits using three PCR techniques: 1) 18S ribosomal DNA (rDNA) 
nested PCR (106), 2) cytochrome b nested PCR (107) and 3)18S rDNA probe-based real-
time PCR (230). The same volume of DNA was used from each extraction method (2-5 µL 
depending on the PCR method). The P. falciparum detection limits were determined as the 
lowest consecutive positive sample in the dilution series. 
8.1.2.10 Data management and statistical analysis 
Data from both study III and IV were double entered in CSPro and transferred to Microsoft 
Excel for validation. The statistical analyses were made in STATA 12 software. All 
frequencies, proportions and odds ratios were calculated with 95% CIs and corresponding p-
values.  
Study III 
Adherence to RDT results was the primary endpoint and was defined as prescription and 
absence of prescription of anti-malarial drugs in RDT positive and negative patients, 
respectively. 
Secondary endpoints included a) sensitivity, specificity, positive predictive values (PPV) and 
negative predictive values (NPV) of RDT compared with both PCR and BS microscopy and 
b) performance of RDT within IMCI in Zanzibar assessed as a sub-group analysis in children 
under five. 
Since blood sampling for BS microscopy and PCR among RDT negative patients only 
included a random sample of 20%, we multiplied the absolute number of observations in 
these groups with a factors of 5.14 and 5.01 in all calculations of RDT sensitivity and 
specificity against PCR and microscopy, respectively. The corresponding CIs were, however, 
based on the true sample size. Statistical significances were stated at the 5% level. 
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Study IV 
The outcomes of the SNP genotyping between extracted DNA from RDT and FP were 
compared by kappa analysis (κ). Since there were many incomplete RDT/PCR pairs, pfmdr1 
copy number variations were compared using Wilcoxon rank-sum test. Statistical 
significance was defined as p <0.05.  
8.2 RESULTS  
Study III 
Among 3890 enrolled patients, 121 (3.1%) were tested positive for malaria by HRP-2 based 
RDT. While 2212 (56.9%) of the total 3890 patients were female, 65 (53.7%) of all RDT 
positive patients were male. Children aged between 5-14 had the highest malaria positivity 
rate (6.1%, 32/528). Seventy-nine (65,3%) of all RDT positive patients were found in 
Micheweni district. However, the distribution of RDT positive patients was not even as 53 
(67.1%) cases were detected at one health facility in Micheweni district.  
Adherence to RDT test result was excellent. All 121 RDT positive, but only 3/3768 (0.1%) of 
RDT negative patients, (all aged >14 year) were prescribed anti-malarial medicine. Health 
workers’ adherence to RDT test result was 99.9%. 
Sensitivity, specificity, positive predictive values (PPV) and negative predictive values 
(NPV) of RDT compared with both PCR and BS microscopy is shown in table 5. 
Overall RDT showed to have a relatively low sensitivity but very high specificity against 
both BS microscopy and PCR. Four out of six RDT negative but BS positive had high 
parasite densities (3573-50290 parasites/mL). We could not detect HRP-2 deletion in these 
samples. More importantly BS microscopy could not detect P. falciparum malaria infection 
among seven patients with both RDT and PCR positive result. Comparing BS and PCR 
resulted in nine BS negative but PCR positive cases.  
Assessment of performance of malaria RDT within IMCI in Zanzibar showed no significant 
difference in children under five compared to other age groups (5-14 years and > 14 years). 
Even though the likelihood of RDT negative patients to receive antibiotics compared to RDT 
positive patients was statistically significant [OR 3.25 (95% CI 2.15–5.01)], among children 
under five, the rate of antibiotic prescription was similar between both groups i.e. 57% and 
58% in the RDT negative and RDT positive group, respectively. Further, children under five 
were overall statistically significantly less likely to receive antipyretics than patients aged 
over 5 years [OR 0.22 (95% CI 0.19–0.26)].  
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Table 5: Sensitivity, specificity, PPV and NPV of RDT against PCR and BS microscopy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*, **Multiplication with factors 5.14 and 5.01  
 
Study IV 
8.2.1 Sensitivity of RDT-DNA extraction methods in In vitro cultured 
parasites 
The detection limit of P. falciparum DNA varied with RDT device and extraction method. 
Chelex-100 extraction performance was best for both RDT devices as well as for DNA 
extraction from FP with a detection limit of two parasites/µL. The detection limit of ABI 
extraction method was 10-fold higher (20 parasites/µL). Generally, the efficiency of DNA 
extraction from SD-Bioline Malaria Ag P.f/Pan was higher than from Paracheck-Pf ®. The 
simple elution method was unsuccessful for DNA extraction from Paracheck-Pf ®. DNA 
extraction from RDTs was generally equal to or better than DNA extraction from an equal 
volume (5 µL) of blood obtained from FP. 
8.2.2 Parasite detection and drug resistance genotyping in field samples 
No significant difference in PCR detection rates in DNA extracted from RDTs and FPs was 
found.  Out of 855 paired RDT and FP field samples, 118 (13.8%; CI 95% 11.4-16.2%) were 
PCR positive in both groups of samples (κ=0.94). Among the RDT negative field samples 
(N=734), three (0.4%; CI 95% 0.0-0.9%) and six (0.8%; CI 95% 0.1-1.5%) were PCR 
positive from RDT and filter paper extracted DNA, respectively. Among the 121 RDT 
positive field samples, 115 (95.0%; CI 95% 91.1-99.0%) and 112 (92.6%; CI 95% 87.8-
97.4%) were PCR positive (κ =0.50). No observed difference was found in the ability of 
detecting low-density parasitaemia (<100 parasites/µ L), statistical significance could not be 
calculated due to small number of low parasitaemias (only 12).  
  PCR + PCR – Total BS+ BS- Total 
RDT + 117 4 121 110 11 121 
RDT - 7* 726* 733 6** 733** 739 
Total 124 730 854 116 744 860 
Sensitivity (95% CI) 76.5% (69.0- 83.9%) 78.6% (70.8–85.1) 
Specificity (95% CI) 99.9% (99.7- 100%) 99.7% (99.5-99.9%) 
Positive predictive value  (95% CI) 96.7% (91.8- 99.1%) 91.7% (84.3-95.4%) 
Negative predictive value (95% CI) 99.0% (98.0- 99.6%) 99.2% (98.8-99.5%) 
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No significance differences in PCR success rates and genotyping in outcomes for the 
respective SNPs in all RDT positive samples were found as shown in table 4. Further, we 
could not detect multiple Pfmdr1 copy number in any sample.  
Table 6: PCR success rates and agreement of genotyping outcomes in field samples 
 RDT PCR success 
rates 
N = 121 (%; CI 95%)  
Filter paper PCR success 
rates  
N = 121 (%; CI 95%) 
Kappa value 
Pfcrt K76T 114 (94.2; 89.9-98.5) 104 (86.0; 79.6-92.3) 0.72 
Pfmdr1 N86Y 112 (92.6; 87.8-97.4) 109 (90.1; 84.6-95.5) 0.85 
Pfmdr1 Y184F 110 (90.9; 85.7-96.2) 107 (88.4; 82.6-94.3) 0.74 
Pfmdr1 D1246Y 113 (93.4; 88.8-97.9) 107 (88.4; 82.6-94.3) 0.77 
Pfmdr1 copy number 84 (69.4; 61.0-77.8) 77 (63.6; 54.9-72.4) - 
8.3 DISCUSSION  
Compared to the results in the previous study from Zanzibar when 30% of all fever cases 
were attributed to P. falciparum malaria (56), the sensitivity of RDT against BS microscopy 
has declined from 92% to 79% whereas the corresponded specificity has increased from 88% 
to 99%. The latter figure may reflect the new low malaria transmission context in Zanzibar 
but the observed low sensitivity of Paracheck-Pf ®, which was below the WHO-FIND 
(foundation of innovative new diagnostics) evaluation (245), is worrying since similar results 
have been reported from other studies (see Table 7). Also, considering the limitations of 
RDTs to detect low parasitaemias, it might not be the ultimate tool for malaria diagnosis in 
these settings (231). 
The low sensitivity of Paracheck-Pf ® RDT can partly be explained by suboptimal 
performance of the test by the study health workers. All these patients had documented 
axillary temperature over 37.5 °C (37.6°C-39.8°C). Whilst two out of six RDT negative but 
BS and PCR positive cases had low parasite density (10 and 50 parasites/µl), the remaining 
four had high parasite densities of 3573, 14420, 25779 and 50190 parasites/mL, respectively. 
Four out of six false negative RDT results were reported from the same health facility that 
had the highest positivity rate among all health facilities in our study. This highlights the 
needs for improved systems for RDT supervision and quality control in primary health care 
facilities for RDT management. Other factors that can explain the low sensitivity of 
Paracheck-Pf ® RDT such as prozone effect i.e. false-negative test results due to antigen 
excess, could not be assessed retrospectively since blood was not available for serial dilution 
(234). Our study confirmed the previous observations from Zanzibar of an excellent 
adherence to RDT results among primary health workers (56) In contract to reports from 
various levels of health care and epidemiological settings in sub-Saharan Africa where health 
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workers’ adherence to negative RDT result was very low (see table 7), our findings indicate 
that the health workers in this study had an excellent adherence to the test results despite the 
fact that 97 out of 100 tests were negative and resources for diagnosing alternative fever 
aetiologies were limited.  
Furthermore, our study shows that RDT can be reliably integrated in the IMCI. There was 
neither any difference in RDT performance nor in adherence to RDT test results in children 
under five compared with other age groups. However, over 55% of antibiotic prescription 
rate among febrile children under five with negative RDT result was observed in this study. 
This is a concern, especially when data from similar settings show that the aetiology of these 
patients’ febrile illnesses is due to viruses and not bacteria (58 and Elfving et al, submitted).   
Table 7: Efficiency of and adherence to Rapid diagnostic test (RDT) results in different malaria endemic 
settings 
Setting 
/country 
Year Type of 
RDT used 
Dominant 
Plasmodium 
species 
Sensitivity 
(versus 
Microscopy) 
Specificity 
(versus 
Microscopy) 
% of over- 
prescription of 
antimalarial 
drugs 
Tanzania 2006-
2007 
Paracheck-
Pf ® 
P. falciparum 65% 88% - 
Tanzania 2007 ParaHIT f 
test (HRP-2 
based) 
P. falciparum 69% 
(Versus PCR) 
100% 
(Versus PCR) 
29%  
Burkina 
Faso 
2006 Paracheck-
Pf ® 
P. falciparum NA NA 80% 
Malawi 2009 Four 
different 
products of 
HRP-2 
based RDTs 
P. falciparum 90%-97% 39%-68% 58%  
Tanzania 2005 Paracheck-
Pf ® 
P. falciparum 95 % 96 % 54% 
Zanzibar 2005 Paracheck-
Pf ® 
P. falciparum 92% 88% 0% 
Zanzibar 
(Study III) 
2010 Paracheck-
Pf ® 
P. falciparum 79% vs. BS 
77% vs. PCR 
100% vs. BS 
and PCR 
0% 
(56, 92, 93, 232, 233)  
(BS= Blood smear, PCR= Polymerase chain reaction) 
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In Study IV we assessed DNA extraction efficiency from two different malaria RDT devices 
and assessed the field applicability of RDT-DNA extraction for molecular surveillance, 
including detection of infections and key genetic markers associated with anti-malarial drug 
resistance. DNA extraction efficiency from in vitro cultured P. falciparum varied with RDT 
device and extraction method. Whilst simple elusion method showed to be unsuccessful for 
DNA extraction from Paracheck-Pf ®, using Chelex-100 and the modified version of 
extraction of ABI-6100 protocol were successful. Our results indicate that for low 
parasitaemias, Chelex-100 in combination with Cytochrome b nested PCR and 18S rDNA 
probe-based real-time PCR is the preferable methods of choice. The disadvantage of Chelex-
100 method is that despite its relative labour intensity the quality of the DNA extracted is 
lower than ABI extraction method which is a high throughput method provides high quality 
DNA and a higher P. falciparum detection level compared to Chelex-100.  Thus, ABI 
extraction could be suitable for analyses of RDT positive, symptomatic malaria patients with 
higher parasitaemia but this is an expensive method that requires special laboratory 
equipment. Finally, simple elution method is the cheapest and fastest alternative but its use 
may be limited by RDT design and choice of PCR. 
The quality of the DNA extracted from RDTs collected in study III was equal to that 
extracted from FP, suggesting that RDT is a reliable alternative for DNA storage. In contract 
to FP, storage of RDT does not require drying, storage in plastic bags and use of desiccants. 
The same device used for malaria diagnosis in daily routine work can be used for both 
malaria case detection and as a reservoir of biological material without involving health 
workers and patients in difficulties associated with research trials. Hence, DNA extracted 
from RDTs collected from field can be used both for molecular surveillance as well as 
detection of low parasitaemias and for RDT quality control.  
A disadvantage of RDT-DNA extraction is the limited amount of biological material (5– 15 
µL blood). This makes RDT-DNA extraction a “one shot operation” with no possibilities for 
re-extraction. Using filter paper usually enables access to a much larger volume of blood (50– 
100 µL).  
8.4 LIMITATIONS  
Study III 
In our study faint bands were interpreted as positive. A study from low malaria endemic area 
in Tanzania suggests that faint band should be regarded as negative especially in low malaria 
endemic setting (235) We did not make any examination of the health workers visual acuity, 
which may have influences the number of false negative results. Further although the 
adherence to the test result in the previous study (56) was good, the high adherence to RDT 
results in our study can be further explained by the extensive training all study health workers 
were provided prior to the start of the study. Another limitation of the study was that we only 
subjected 20% of all negative patients for further PCR and BS tests. Despite the statistical 
adjustments by using factor five in sensitivity and specificity calculation, it might be a 
weakness that we did not test all patients with BS and PCR. 
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Study IV 
As the DNA extraction was conducted in accordance to the previously published methods, 
the same volume of elution buffer was not used in all the three extraction methods. The 
volume of elution buffer in the ABI method was four times higher compared to the simple 
elution method meaning that DNA was four times more diluted in the ABI method. A DNA 
quantification of the extracts with a qPCR method comparing the Ct-values may have had 
added more information to this study. 
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9 CONCLUSIONS 
9.1 OVERALL CONCLUSION 
During the conduct of the studies in this thesis, malaria elimination was not achieved in 
Zanzibar. However, following implementation of effective and sustainable tools 
and interventions with high coverage and uptake, Zanzibar has reached a state of malaria pre-
elimination.  Additional tools and interventions are necessary for further reduction of malaria 
transmission towards malaria elimination. 
9.1.1 Specific conclusions 
Study I 
• Following implementation of combined malaria control interventions, Zanzibar has 
reached the state of malaria pre-elimination. 
 
• Reducing malaria transmission further to achieve malaria elimination requires new 
tools and strategies including reorientation of the current malaria control activities 
with greater need of financial support.  
Study II 
• Effective coverage of vector control interventions in Zanzibar remains high despite 
the general perception of reduced malaria burden by the caretakers.  
 
• Sustaining high effective coverage of vector control interventions, which is critical in 
reaching malaria elimination in Zanzibar, can be achieved by maintaining effective 
delivery of these interventions. 
Study III 
• The sensitivity of HRP-2 based RDT in the hands of primary health care workers 
compared with both PCR and microscopy for P. falciparum case detection was 
relatively low, highlighting the need for improved quality control of RDT use in 
primary health care facilities and more sensitive point-of-care malaria diagnostic tools 
in the new epidemiological context of low malaria transmission in Zanzibar. 
 
• Adherence to test results with anti-malarial treatment was excellent. Further, the 
results show that RDT can be reliably integrated in IMCI as a tool for improved 
childhood fever management. 
Study IV 
• RDT is a valuable source of parasite DNA which can be used for improved malaria 
case detection, molecular drug resistance surveillance as well as RDT quality control.  
 
• The purpose of DNA extraction should be considered when choosing which 
extraction method best suits the type of samples to be analysed.   
 66 
10 PERSONAL REFLECTIONS  
According to the WHO, the total sum of the international and domestic funding for malaria 
control and elimination in 2013 was only half of the total US$ 5.1 billion needed to achieve 
global targets for malaria control and elimination (15).   
While we rightfully discuss the recent years’ global successes in malaria control and 
feasibility of malaria elimination in some countries, we need to be reminded of the less 
favourable development in malaria control in some other countries in Africa.  
The internal and regional conflicts have had devastating impact on the already depleted 
malaria situation in some regions in Africa. In ten countries in the Central Africa, the number 
of the malaria cases and admissions has increased compared to the previous years. (15). In 
The Central African Republic, the number of children who were sleeping under a mosquito 
net before the eruption of the recent internal conflict in 2013 was around 30% and access to 
malaria treatment was limited. Following the crisis the situation has deteriorated further as 
many malaria treatment centres were destroyed and health workers had to flee  (256)  
The situation in Zanzibar is much different from the above mentioned. Zanzibar’s efforts in 
fighting malaria have been successful resulting in a rapid transition from a high to a low 
malaria endemic setting in less than a decade.  Our studies show a good trust in the health 
services by the population with high adherence to vector control measures. The health 
workers too, show a high confidence in and adherence to the malaria treatment guidelines 
provided by ZAMEP. Further, the access to the public health facilities is relatively easy as the 
transport links in most areas in Zanzibar are good. 
However, the feasibility of achieving malaria elimination must be assessed with regards to 
different characteristic conditions for different countries (257). In order to reach all malaria 
infections, Zanzibar needs to improve both the passive and active case detection by using 
more sensitive point-of-care diagnostic tools (203). Additionally, development of an effective 
system for detection and management of imported malaria cases as well as a sustained high 
coverage of the vector control measures are needed. All these interventions are laborious and 
costly. Having turned Zanzibar into an unstable low malaria endemic setting with non 
existing or low herd immunity, malaria resurgence would be devastating for Zanzibar and 
would rise questions whether a long-term malaria control is possible elsewhere in Africa 
(158, 191). Therefore, adapting either the strategy of sustained control i.e. maintaining and 
marginally improving the current low malaria transmission status or setting up the goal of 
malaria elimination in a short term must be done cautiously and with regards to the feasibility 
of either strategies. 
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